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LSS: Lanosterol Synthase 
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La hipercolesterolemia familiar (FH) es un desorden genético autosómico dominante 
caracterizado por unos niveles elevados de lipoproteínas de baja de densidad (LDL) en sangre y 
un aumento en el riesgo de enfermedades cardiovasculares tempranas como por ejemplo la 
aterosclerosis. En esta tesis, se ha estudiado la fisiopatología de la FH a nivel celular usando 
como modelo fibroblastos de la piel de pacientes afectados por FH los cuáles portan una 
mutación en el receptor de LDL, la cual es una de las mutaciones más comunes en la 
enfermedad. 
Los fibroblastos de los pacientes afectados por la FH mostraron una menor captación de 
LDL asociado con una mayor cantidad de colesterol intracelular y una deficiencia de coenzima 
Q10 (CoQ10), advirtiendo una desregulación en la ruta del mevalonato. 
La deficiencia secundaria de CoQ10 provoca un defecto en el funcionamiento mitocondrial 
así como la activación de procesos mitofágicos de forma continuada. La mitofagia constante 
altera el flujo autofágico e induce la activación del inflamasoma junto a un aumento de la 
producción de citoquinas en las células mutantes. Todas las alteraciones patológicas en los 
fibroblastos de FH fueron además reproducidos en un modelo de células endoteliales, las más 
afectadas en los procesos ateroscleróticos, mediante el silenciamiento del receptor de LDL. 
Tanto el aumento intracelular de colesterol como la disfunción mitocondrial en 
fibroblastos con FH fueron parcialmente restaurados mediante la suplementación externa de 
CoQ10. La desregulación de la ruta del mevalonato en FH, incluyendo el aumento de expresión 
de enzimas colesterogénicas y la disminución de la expresión de genes relacionados con la 
biosíntesis de CoQ10, fueron también corregidos por el tratamiento de CoQ10. 
Por ello, en estas tesis se establece que los bajos niveles de CoQ10 y la disfunción 
mitocondrial pueden jugar un papel crucial en la fisiopatología de la aterosclerosis temprana 
en FH y que el diagnóstico de la deficiencia de CoQ10 y las alteraciones mitocondriales 
también podrían ser importantes para establecer un tratamiento temprano suplementado con 








3.1. Cholesterol  
 Although the word “cholesterol” carries negative connotations for a lot of people, this 
substance actually has important physiologic functions. The reason is because cholesterol 
metabolism dysregulation can produce serious metabolic diseases and even death.   
 The word “cholesterol” comes from the Greek “khole” (bile) and “stereos” (stiff). 
Cholesterol was first identified in 1769  by François Poulletier de la Salle in human gallstones. 
However, it was not until 1815 that chemist Michel Eugène Chevreul named the compound 
"cholesterine" (Olson, 1998). 
Since the past century, cholesterol has been related with numerous diseases such as 
atherosclerosis (Yin et al., 2015), Alzheimer’s disease (Banerjee & Mukherjee, 2018), cancer 
(Murai, 2015) or multiple sclerosis (Zhornitsky, McKay, Metz, Teunissen, & Rangachari, 2016). 
Despite its implications in those medical alterations, cholesterol is necessary and plays an 
essential role in the organism. Cholesterol most important functions are:   
1.  Regulator of the membrane structure and function (Xiaoyan Zhang et al., 2011). 
2. Steroid hormones precursor (Midzak & Papadopoulos, 2014). 
3.  Bile acid and salt formation (Jing Wang, Bie, & Ghosh, 2016). 
4. Vitamin D synthesis (Prabhu, Luu, Sharpe, & Brown, 2016). 
5. Endocytosis (Yue & Xu, 2015). 
6. Cell signaling (Fukui, Ferris, & Kahn, 2015). 
7. Electrical impulse enhancer (Saher & Stumpf, 2015).  
 Cholesterol is a 27-carbon polycyclic lipid molecule organized in four fused rings in a 
planar conformation. It has one unsaturated double bond (C5-C6), one β-hydroxyl substitution 
(C3) and a simple 8-carbon aliphatic tail (Figure 1). Although its lipid molecule nature, 
cholesterol cannot be used as energy source since no enzymes exist that can break the sterol 





Figure 1.Cholesterol structure. Cholesterol is a 27-carbon, planar, 3β-hydroxylated sterol molecule. 
These structural features are essential, since minor modifications block cholesterol biological 
functioning. 
 
Cholesterol is an hydrophobic molecule  and therefore it is exclusively found in 
membranes and other lipid and/or lipid-protein complexes (Hofmann et al., 2014). Within 
membranes, cholesterol interacts with phospholipids and sphingolipid fatty acyl chains while 
simultaneously increasing membrane bilayer rigidity and reducing water and ion membrane 
permeability (Choubey, Kalia, Malmstadt, Nakano, & Vashishta, 2013). At the subcellular level, 
cholesterol is heterogeneously distributed, with only up to 1% of total cell cholesterol present 
in the endoplasmic reticulum (ER) (Stevenson, Huang, & Olzmann, 2016) , almost 80% in the 
plasma membrane and the rest is organized in lipid droplets or lipoproteins (Das, Brown, 
Anderson, Goldstein, & Radhakrishnan, 2014). In the plasma membrane, cholesterol can reach 
the 20% of total lipid mass and appears to be critical for its organization and function (Rituper 
et al., 2013). In fact, membrane microdomains called “lipid rafts”, which are dynamic 
protein/lipid assemblies that drift in the liquid-disordered membrane bilayer and are 
important for extracellular ligand binding as well as for intracellular signal transduction 
(Sonnino & Prinetti, 2013), can only be formed when membrane cholesterol concentration 
achieves a 10% threshold content. Taken together, these reasons make cholesterol an 







3.2. Cholesterol homeostasis 
 
3.2.1. The mevalonate pathway 
 
3.2.1.1. Cholesterol biosynthesis 
Cholesterol is either supplied from the diet (exogenous) or synthesized de novo by 
many cells of the body (endogenous). The dietary intake of cholesterol is limited, and 
therefore the physiological requirements for cholesterol are provided mostly through de novo 
synthesis. Almost all cells are involved in the synthesis of cholesterol, with the liver accounting 
for as much cholesterol as non-hepatic tissues combined (Dietschy, Turley, & Spady, 1993).  
The mevalonate pathway is one of the most important metabolic networks in the cell; 
it provides essential cell constituents, including cholesterol, some of its branches produce key 
metabolites, such as geranylgeranyl pyrophosphate and farnesyl pyrophosphate, both involved 
in the biosynthesis of terpenes and terpenoids necessary for normal cell metabolism 
(Marschalek et al., 2015). In the last steps of the cholesterol pathway, the vitamin  D precursor, 
7-dehydrocholesterol (7-DHC), is also synthetized (Kühn, Hirche, Geissler, & Stangl, 2016). 
Importantly, isoprene intermediates in the mevalonate pathway generate a variety of other 
bioactive molecules like dolichol and ubiquinone. 
Cholesterol is synthesized from its precursor unit acetyl-coenzyme A (CoA) via a 
complex metabolic pathway (Joseph L. Goldstein & Brown, 1990). Eighteen acetyl CoA units 
containing 36 carbon (C) atoms are utilized to synthesize one molecule of cholesterol; which 
contains 27 C atoms and 46 hydrogen (H) atoms. Seven H atoms are incorporated into the 
cholesterol molecule directly from water while another 15 atoms are inserted from 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. H atoms from water may also 
become incorporated into substrates that later generate cytosolic acetyl CoA used for 
cholesterol biosynthesis. The 3-hydroxy-3-methyl-glutaryl CoA (HMG-CoA) reductase  (HMGCR) 
is the rate-limiting enzyme in cholesterol synthesis (Rodwell, Nordstrom, & Mitschelen, 1976).  
 Cholesterol is synthesized in the ER by the action of over 30 enzymes organized in the 
mevalonate pathway (Figure 4) whose first part involves four fundamental steps: 
  1.   Condensation acetyl-CoA units to form HMG-CoA. 
2.  HMG-CoA reduction mediated by NADPH -oxidase to generate mevalonate. 
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3.  Conversion of mevalonate into activated isoprenoids 3-isopentenyl pyrophosphate 
and dimethylallyl pyrophosphate. 
4. Polymerization of six isoprenoids units into squalene.  
Next, linear squalene undergoes series of oxygenation and cyclization to form 
lanosterol. From this precursor, cholesterol is synthesized in a 19-step process involving the 
activity of nine different enzymes. The last steps of cholesterol synthesis have been divided 
into two pathways and can proceed via lathosterol and 7-dehydrocholesterol (Kandutsch–
Russell pathway) (KANDUTSCH & RUSSELL, 1960) or via desmosterol to cholesterol (Bloch 
pathway) (Bloch, 1992). These pathways share the same enzymatic steps but differ in the stage 
at which the C-24 bond is reduced.   
 
3.2.1.2. Coenzyme Q10 biosynthesis 
One the most important molecules in the cell that requires a mevalonate pathway 
metabolite is the ubiquinone. Ubiquinone or coenzyme Q10 (CoQ10) is known as a versatile 
molecule because its many functions on the organism. CoQ10 is a benzoquinone ring 
conjugated to a ten units long isoprenoid chain making it a hydrophobic molecule that can act 
as a great electron carrier and free radical scavenging antioxidant (Acosta et al., 2016).  CoQ10 
is mainly required in the mitochondria as electron carrier in the mitochondrial respiratory 
chain (MRC). MRC provides, through oxidative phosphorylation, the capacity to synthesize 
adenosine triphosphate (ATP) which is essential for cellular function. Only just a 30%  (Gnaiger, 
2009) of CoQ10 is protein bound which are thought to be part of the MRC. The free 
mitochondrial CoQ10 pool may serve to other functions like lipophilic antioxidant (Bentinger, 
Brismar, & Dallner, 2007), permeability transition pore opening regulator and maintenance of 
body temperature via its role as a cofactor for the mitochondrial uncoupling proteins (López-
Martín et al., 2007).   
The biochemical pathway responsible for CoQ10 biosynthesis is still incompletely 
identified. In mammals, the precursor of the quinone ring is only the 4-hydroxibenzoate, which 
is derived from tyrosine through an uncharacterized set of reactions. On the other hand, the 
isoprenoid tail biosynthesis is well known and it is synthesized through the mevalonate 
pathway, which is common also to cholesterol biosynthesis (Bentinger, Tekle, & Dallner, 2010). 
Specifically, after the decarboxylation of mevalonate pyrophosphate yields isopentenyl 
pyrophosphate, which is the precursor of farnesyl pyrophosphate and also the building block 
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for the biosynthesis of dolichol and the side chain of CoQ10. Therefore, alterations in the 
mevalonate pathway not only will affect cholesterol but CoQ10 related cellular mechanisms. 
The CoQ10 biosynthesis involves a multi-subunit protein complex (Coq1 to Coq10) 
localized in the inner mitochondrial membrane (Tran & Clarke, 2007).  The polyisoprenoid 
chain is synthesized by Coq1, and its length, depending on the species, may range from 6 
(CoQ6) to 10 (CoQ10) isoprene units. This isoprene product is then condensed to a 4-
hydroxibenzoate-derived benzoquinone ring by Coq2 (Forsgren et al., 2004); while Coq3, Coq5, 
Coq6, and Coq7 are involved in methylation, decarboxylation, hydroxylation and deamination 
reactions (Tran & Clarke, 2007). Coq8 is an atypical protein kinase essential for 
phosphorylation of Coq3, Coq5 and Coq7 (Pierrel et al., 2010).  Coq9 is a lipid-binding protein 
necessary to stabilize Coq7 and apparently controls the deamination of CoQ10 intermediates 
that derive from para-aminobenzoic acid (He et al., 2015). Coq10 is a polypeptide that binds 
CoQ10 and facilitates both de novo CoQ10 biosynthesis and respiratory electron transport 
probably directing the localization of CoQ10 within the mitochondrial membrane (Barros et al., 
2005). Finally, the function of Coq4 is still unknown, but there is evidence that it is required for 
the assembly and stability of the CoQ10 biosynthetic complex (Barros et al., 2005). 
Statins, the famous cholesterol-reducing drug, are effective because they are capable 
to inhibit the mevalonate pathway through HMG-CoA inhibition, therefore inhibiting all the 
cholesterol and related metabolites biosynthesis. Although it is a great choice in most 
hypercholesterolemia pathologies, statins have been related with myalgia. Several hypothesis 
support the idea of reduced production of farnesyl pyrophosphate, an intermediary used in 
the biosynthesis of CoQ10. Statins will be discussed in the following sections of the thesis. 
 
3.2.2. Cholesterol intestinal absorption 
In addition to being endogenously synthesized, cholesterol is incorporated into the cell 
from plasma lipoproteins by cell surface receptor mediated endocytosis. Cholesterol is a 
hydrophobic molecule, and its intestinal absorption requires emulsification, hydrolysis (of 
dietary esterified cholesterol), micellar solubilization, and uptake within enterocytes. 
Furthermore, intracellular cholesterol is partly re-esterified and finally delivered to the 
bloodstream. Cholesterol present in the intestinal lumen derives from several sources, 
including diet, bile, intestinal secretion and desquamated epithelial cells. In humans consuming 
Western type diets, 300–500 mg dietary cholesterol enters the intestinal lumen per day, 
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whereas the contribution of biliary cholesterol has been estimated to be approximately 800– 
1200 mg per day. 
 
In healthy humans normally approximately 50% of intestinal cholesterol is absorbed 
(Sudhop et al., 2002) and represents the 50% of the cholesterol in the organism. Cholesterol 
entering the small intestinal lumen, and subsequently absorbed by the enterocytes (Figure 2), 
is derived from three major sources: diet, bile, and intestinal epithelial sloughing (D. Q.-H. 
Wang, 2007). The duodenum and proximal jejunum are the major sites of absorption (Arnesjö, 
Nilsson, Barrowman, & Borgström, 1969). For the cholesterol to be absorbed, micellar 
solubilization must take place (Woollett et al., 2006). Dietary cholesterol is partly esterified 
(<15%) in comparison to biliary cholesterol which is predominantly unesterified. This requires 
the dietary cholesteryl esters (CE) to be de-esterified by pancreatic carboxyl ester lipase (CEL) 
before cholesterol can be packed and transported to the brush border of enterocytes (van der 
Wulp, Verkade, & Groen, 2013). It must be noted that since the biliary pool of unesterified 
cholesterol is larger than the esterified dietary pool of cholesterol, targeted inhibition of the 
pancreatic lipolytic enzymes becomes ineffective in reducing cholesterol absorption (D. Q.-H. 
Wang, 2007). Two enzymes mainly control the intestinal uptake and transport process of 
sterols: acetyl-CoA acetyltransferase (ACAT), which facilitates intracellular cholesterol 
esterification, and the microsomal triglyceride transfer protein (MTTP), which is involved in 
intestinal chylomicron assembly (D. Q.-H. Wang, 2007). 
 
The Niemann–Pick C1-like 1 (NPC1L1) transporter facilitates the uptake of cholesterol 
and plant sterols/ stanols (Davis & Altmann, 2009). NPC1L1 is located in the brush border 
membrane of enterocytes in the proximal jejunum of the small intestine. The suppression of 
the NPC1L1 gene reduces a 70 and 90 % in cholesterol and plant sterol/stanol absorption, 
respectively (Davis et al., 2004). The non-effluxed intracellular cholesterol translocates to the 
endoplasmatic reticulum and subsequently gets esterified by ACAT (R. G. Lee, Willingham, 
Davis, Skinner, & Rudel, 2000). The esterified cholesterol is then incorporated into chylomicron 
together with triacylglycerols (TAG), phospholipids, and to apolipoprotein B48 by MTTP to be 
delivered to the lymph (Gordon & Jamil, 2000). In addition, enterocytic cholesterol can be 
transferred to apolipoprotein A1 (apoA1) high density lipoprotein (HDL) particles via ATP-





Figure 2.  Cholesterol absorption and biosynthesis pathways. Dietary cholesterol entering the proximal 
intestinal lumen is composed of both cholesterol and cholesterol esters. Cholesterol esterase catalyses 
the hydrolysis of CE to free cholesterol and contributes to the formation of lysolecithin-containing 
micelles. Cholesterol in micelles both from the dietary source and from hepatic cholesterol are 
subsequently available for uptake via the proximal intestinal lumen. The process of cholesterol uptake is 
mediated by a protein transport mechanism, as evidenced by the kinetic processes involved, the sterol 
specificity and the fact that the drug ezetimibe inhibits cholesterol uptake.  The NPC1L1 is the crucial 
mediator in the cholesterol absorption and has been shown to reside on the apical surface of the 
intestinal enterocytes. Cholesterol re-esterification occurs within the enterocytes via ACAT and the 
cholesterol is packaged into chylomicrons and secreted into the lymph. Owing to the high amounts of 
NPC1L1 expression in the liver, it is likely that the cholesterol transporter contributes to the re-uptake of 
cholesterol from micelles in bile and this process is likely to be inhibited by ezetimibe. Simultaneously, 
the liver hepatocytes synthesize cholesterol via a complex process involving at least 30 enzymes.  
NPC1L1; Niemann-Pick C1-like protein 1, ACAT; Acyl-CoA Cholesterol Acyltransferase, FC; Free cholesterol, HDL; 





3.2.3. Cholesterol cell uptake 
As the chylomicrons reach the circulation via the lymph some of the triglycerides are 
hydrolyzed by lipoprotein lipase and the chylomicron remnants are taken up by hepatocytes. 
In turn, hepatocytes secrete lipids in very low density lipoproteins (VLDL) particles that are 
processed in the circulation into low density lipoproteins (LDL), the main lipoprotein that 
delivers cholesterol to the peripheral cells.  
Lipoprotein transport of cholesterol in plasma plays a physiological role for essential 
energy production, cell membrane, and hormone synthesis. Cells readily utilize cholesterol by 
internalizing lipoprotein ligands containing chylomicron, LDL, intermediate-density lipoprotein 
(IDL), or VLDL mediated by the LDL receptor (LDL-R) family of membrane receptors. Brown and 
Goldstein first dissected the now prototypical LDL-R pathway (Figure 3) (J L Goldstein & Brown, 
1974a), demonstrating that specific cell surface receptors are required for extracellular ligand 
endocytosis (Brown & Goldstein, 1986). In this model, circulating LDL binds to LDL-R on the cell 
surface and are incorporated, as a whole lipoprotein-receptor complex, via clathrin-coated 
vesicles, into endolysosomal compartments for further processing. At this level, LDL-R is 
recycled back to the surface, whereas LDL particles are fully degraded into their individual 
components. More specifically, LDL-derived cholesteryl esters are de-esterified to form free 
cholesterol and fatty acids by the action of lysosomal acid lipase. LDL-R-mediated endocytosis 
has provided much of our understanding of lipoprotein clearance, and its defect is a major 








Figure 3. Cellular cholesterol homeostasis. Vesicular uptake of lipoproteins is essential for lipoprotein 
and lipid metabolism. This process is regulated by the LDL-R family of proteins. Recognition of 
apolipoproteins by the receptor at neutral pH initiates the internalization, followed by LDLRAP1 (LDL-R 
adaptor protein; also known as ARH) binding of the cytoplasmic NPxY motif and clustering of receptor-
ligand complexes into clathrin-coated pits. Coated vehicle dispenses to endosomes, in which acidic 
condition activates the release of internalized ligands from the receptor. Released ligand particles travel 
further to lysosome, in which ligand is degraded by enzyme. The receptors recycle back to the cell 
surface. Internalized cholesterol reduces cholesterol biosynthesis and LDL-R transcription by inhibiting 
SREBP-2. PCSK9 binds to LDL-R, which is targeting LDL-R to lysosome for degradation. De novo 
lipogenesis is also reduced by inhibition of SREBP-1c. TG undergoes adipogenesis to form lipid droplet. 
LDL-R, Low Density Liprotein Receptor; LDLRAP1, LDL-R Adaptor protein 1; SREBP, Sterol regulatory element-binding 
protein; PCSK9, Proprotein convertase subtilisin/kexin type 9; TG, Triglycerides; CE, Cholesterol Esters; FC, Free 







LDL-R is a cell membrane glycoprotein that functions in the binding and internalizing of 
circulating cholesterol-containing lipoprotein particles. LDL-R is ubiquitously expressed and is a 
key receptor for maintaining cholesterol homeostasis in mammals. LDL-R-mediated 
endocytosis is essential for lipoprotein and lipid metabolism (J L Goldstein & Brown, 1974a). 
Recognition of apolipoprotein B (apoB) of LDL particles occurs with a stoichiometry of a single 
copy of apoB per one LDL particle per receptor monomer (Wiklund, Dyer, Tsao, & Curtiss, 
1985). VLDL, IDL, HDL, and chylomicron remnant are also recognized by LDL-R at neutral pH 
(Innerarity, Mahley, Weisgraber, & Bersot, 1978). Coated vehicle dispenses to endosomes with 
LDL-R and LDL-R adaptor protein (LDLRAP1), connecting the LDL-R family protein and the 
endocytic machinery; thereby, acidic condition activates dissociation of internalized ligands. 
Released ligand particles further travel to the lysosome, in which the ligand is degraded by 
enzyme, while the receptors recycle back to the cell surface. LDL particles trigger three steps 
after internalization (Brown & Goldstein, 1976) : 
 
1.  Reduces gene expression of HMGCR to suppress cholesterol biosynthesis. 
2. Enhances activity of ACAT to reduce toxic free cholesterol. 
3. Suppresses LDL-R synthesis to reduce LDL uptake via sterol regulatory element-
binding proteins (SREBP). 
 
 The LDL-R dissociates from LDL in the early endosome and is recycled back to the 
plasma membrane by vesicular mechanisms that depend on small G-proteins from the Rab 
family, such as Rab8 (Linder et al., 2007) and Rab11 (Hölttä-Vuori, Tanhuanpää, Möbius, 
Somerharju, & Ikonen, 2002). The non-recycled contents of the early endosome, namely 
cholesterol, proceed to the late endosome/ lysosome and upon release, are delivered to other 
membranes, such as the plasma membrane, ER, and mitochondria. Two proteins, Niemann–
Pick disease, type C1 and C2 (NPC1 and NPC2, respectively), are crucial for moving cholesterol 
out of the late endosomal system and into the cytosol. A deficiency of either protein leads to 
Niemann–Pick type C disease, which is characterized by an accumulation of free cholesterol in 
late endocytic organelles (Ory, 2004). Although the exact roles of these proteins are not clear, 
it is predicted that NPC2, a small soluble protein, accepts cholesterol in the late endosomal 
lumen and transports it to membrane-bound NPC1, which helps transfer cholesterol out of the 
endosomal system (M. L. Wang et al., 2010).
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Figure 4. Cholesterol synthesis in the mevalonate pathway. First, HMG-CoA and mevalonate are formed from acetyl-CoA. The conversion of HMG-CoA into 
mevalonate is catalyzed by HMG-CoA reductase. Mevalonate is converted into activated isoprenoids isopentenyl pyrophosphate and methyallyl 
pyrophosphate (not shown), which, in turn, originate farnesyl pyrophosphate and squalene. The subsequent cyclization and oxygenation of squalene to 
lanosterol involves the action of squalene monooxygenase and lanosterol synthase and requires molecular oxygen and NADPH. Finally, the generation of 
cholesterol involves lanosterol: 1) demethylation at C4α, C4β, and C14; 2) isomerization of the Δ8(9) double bond to a Δ7 double bond; 3) desaturation to 
form a Δ5 double bond; and 4) reduction of Δ14, Δ24, and Δ7 double bonds. Importantly, the reduction of Δ24 double bond, catalyzed by 3β-hydroxysterol 
Δ24-reductase (DHCR24) can happens at any level below lanosterol, originating two parallel pathways and resulting in either 7-dehydrocholesterol or 
desmosterol, which are reduced to cholesterol by DHCR7 or DHCR24, respectively (Cortes et al., 2014). 
HMG-CoA, 3-hydroxy-3-methyl-glutaryl CoA;  NADPH, Reduced Nicotinamide adenine dinucleotide;  DHCR7,  7- dehydrocholesterol reductase; DHCR24, 24-dehydrocholesterol 




3.2.4. Cholesterol regulation 
 
3.2.4.1. Cellular consequences of cholesterol accumulation 
 Cholesterol may be deleterious or even lethal for cells and many protective 
mechanisms have evolved to prevent this cellular toxicity. The underlying causes of cholesterol 
cytotoxicity are not completely clear. A physiological free cholesterol (FC)/phospholipid ratio in 
cellular membranes is necessary to maintain proper membrane fluidity, or more precisely, a 
proper range of membrane fluidities (K Simons & Ikonen, 2000) . The degree of saturation of 
the fatty acyl moieties of membrane phospholipids is the major determinant of the fluidity of 
lateral membrane domains, which consist of well-packed, detergent-resistant liquid-ordered 
rafts and more fluid, detergent-soluble liquid-crystalline regions (Kai Simons & Ehehalt, 2002). 
Nonetheless, the interaction of the hydrophobic rings of cholesterol with these fatty acyl 
chains has important effects (Maxfield & Wüstner, 2002).In particular, the ability of cholesterol 
to pack tightly with saturated fatty acyl groups of membrane phospholipids is critical for the 
formation of liquid-ordered rafts (K Simons & Ikonen, 2000). When the FC/phospholipid ratio 
rises above a physiological level, the liquid-ordered rafts may become too rigid, and the liquid-
crystalline domains may begin to lose their fluidity. These alterations affect certain integral 
membrane proteins that require conformational freedom for proper function and that can be 
inhibited by a high FC/phospholipid ratio (Yeagle, 1991). High FC levels might therefore be 
proposed to kill cells in part by inhibiting one or more integral membrane proteins whose 
function is blocked or altered under conditions of high membrane rigidity (Ira Tabas, 2002). 
Models for FC-induced cell death are summarized in Table 1. 
Excess membrane cholesterol may also disrupt the function of signaling proteins that 
reside in membrane domains (Pierini et al., 2003). One interpretation of these data is that 
excess plasma membrane cholesterol disrupts the function of certain signaling molecules that 
normally reside in non-raft domains. Experiments in vitro with model membranes suggest that, 
in membranes already enriched in sphingolipids, increasing the FC concentration even 
modestly above the physiological concentration can actually suppress the formation of 




Table 1. Potential mechanisms of FC-induced cytotoxicity. Modified from (Ira Tabas, 2002) 
Event Consequence Reference 
Loss of membrane fluidity Dysfunction of integral 
membrane proteins and 
exocytosis 
(Bogan, Xu, & Hao, 2012) 
Disruption of membrane 
domains 
Disruption of signaling events (Tomita et al., 2014) 





(Corr, Cunningham, & 
Dunne, 2016) 
Formation of toxic oxysterols  Oxidative damage, 
carcinogenesis 
(Jusakul, Yongvanit, 
Loilome, Namwat, & 
Kuver, 2011) 
 Alteration of gene expression Change in balance of survival 
vs. death proteins 
(LIM, PARAJULI, DUONG, 
CHOI, & HAN, 2014) 
 
Other mechanisms of cellular toxicity associated with FC accumulation include 
intracellular cholesterol crystallization, oxysterol formation (Björkhem, 2002) and triggering of 
apoptotic signaling pathways (I Tabas, 1997). Cholesterol crystals form when the 
FC/phospholipid ratio reaches a very high level. Intracellular cholesterol crystals can probably 
damage cells by physically disrupting the integrity of intracellular structures (Corr et al., 2016). 
Excess intracellular FC accumulation can also promote the oxidation of cholesterol to 
oxysterols, some of which may be cytotoxic (Khatib & Vaya, 2014). Finally, FC overloading of 
macrophages can trigger a series of apoptotic pathways (Afonso et al., 2014) which leads to 








3.2.4.2. Cholesterol biosynthesis regulation 
The regulation of cholesterol homeostasis involves a complex interplay between a 
growing list of proteins that act to sense and respond to changing levels of cellular cholesterol 
(Figure 5). These proteins may be regulated by cholesterol itself or by certain cholesterol 
intermediates or derivatives. 
While the majority of cellular cholesterol resides in the plasma membrane, most of the 
cholesterol homeostatic machinery is located in the ER. Among these are the sterol regulatory 
element-binding protein 2 (SREBP2), the master transcription factors in cholesterol 
homeostasis, and its associated regulatory proteins. These include SCAP (SREBP cleavage-
activating protein), which complexes with SREBP2 in the ER membrane when cholesterol levels 
are low and escorts it to the Golgi for proteolytic activation; INSIG 1 and 2 (insulin-induced 
gene), which retains SCAP in the ER when cellular cholesterol levels are sufficient or in excess. 
Most cholesterol synthesis enzymes, including the two rate-limiting enzymes HMGCR and 
squalene monooxygenase (SM), also reside in the ER, as well as the cholesterol esterification 
enzyme ACAT, which esterifies excess cholesterol for storage (Howe et al., 2016).  
The SREBP family of transcription factors control cholesterol and lipid metabolism and 
play critical roles during adipocyte differentiation and insulin-dependent gene (P. J. 
Espenshade, 2006; Horton, Goldstein, & Brown, 2002). The family consists of three different 
SREBP proteins, SREBP1a, SREBP1c and SREBP2. The SREBPs are synthesized as large precursor 
proteins that are inserted into the ER membrane through two membrane-spanning domains 
(Bengoechea-Alonso & Ericsson, 2007). The membrane-associated proteins are 
transcriptionally inactive. In the ER, the C terminus of the SREBP interacts with SCAP, which 
functions as a sterol sensor (Edwards, Tabor, Kast, & Venkateswaran, 2000; Joseph L. 
Goldstein, DeBose-Boyd, & Brown, 2006). In sterol-depleted cells, SCAP escorts the SREBPs 
from the ER to the Golgi, where they are processed by two membrane-associated proteases, 
the site 1 and site 2 proteases (SIP), which release the mature forms of the proteins. These 
transcriptionally active fragments of the SREBPs are translocated to the nucleus, where they 
bind to the promoters of SREBP target genes, including genes involved in the synthesis and 
metabolism of cholesterol. In addition, transcription of the genes encoding SREBP1c and 
SREBP2 is enhanced by SREBPs by a feed-forward mechanism that requires functional SREBP 
binding sites in the promoters of these genes. When cholesterol builds up in the ER 
membranes, the SCAP/SREBP complex is retained in the ER, the proteolytic activation of 
SREBPs is stopped, and the expression of SREBP target genes declines. Thus, the amount of 
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cholesterol in cells is controlled by a tightly regulated feedback system. This regulatory system 
extends beyond the SREBPs, since HMGCR, the rate-limiting enzyme in cholesterol synthesis, is 
also controlled by sterol-dependent proteolysis (Joseph L. Goldstein et al., 2006). The feedback 
regulation of SREBPs is complemented by the rapid ubiquitin-dependent degradation of the 
active transcription factors in the nucleus.  
Figure 5. Interplay of cholesterol homeostatic machinery.  Cholesterol is synthesized from Ac-CoA in 
the ER (1) or taken up through the LDL-R (2). When sterol levels are low, INSIG dissociates from SCAP, 
enabling SCAP to escort SREBP (3) to the Golgi for processing by Site-1 and Site-2 proteases (4), SCAP is 
recycled back to ER. This releases an SREBP TF that translocates to the nucleus and upregulates SREBP 
target genes (5). These include HMGCR, SM and LDL-R. When sterol levels are high, cholesterol 
negatively regulates SM and oxysterols negatively regulate HMGCR, causing their degradation. 
Cholesterol binds to SCAP and erlins -1 and -2, and oxysterols bind to INSIG, causing the retention of 
SCAP/SREBP in the ER. Oxysterols, also act as ligands for the LXR-RXR heterodimer, releasing the LXR TF 
and upregulating transcription of LXR target (6) involved in cholesterol efflux. These include ABCA1 and 
ABCG1, which synergise to export cholesterol from the cell (7), and IDOL, which mediates degradation of 
LDL-R (8). Excess cholesterol can also be esterified by ACAT for storage in an inactive form (9). 
ER; Endoplasmic Reticulum, LDL-R; Low Density Lipoprotein Receptor, INSIG; Insulin induced gene 1, SCAP; SREBP 
cleavage-activating protein, SREBP; Sterol regulatory element-binding protein cleavage-activating protein, TF; 
Transcription factor, SM; Squalene Monooxigenase, LXR; Liver X Receptor, ACAT; Acyl-CoA cholesterol 




The sterol-dependent regulation of SCAP and HMGCR is dependent on the sterol-
sensing domains found in the transmembrane domains of these proteins. In the case of SCAP, 
direct binding of cholesterol to its sterol-sensing domain induces a conformational change in 
the protein (Feramisco et al., 2005). As a result, SCAP can no longer interact with the coat 
complex protein 2 (COPII) coat proteins Sar1 and Sec23/24, and the SCAP/SREBP complex is 
not incorporated into COPII-coated vesicles (Sun, Li, Goldstein, & Brown, 2005). Consequently, 
SREBPs are not transported to the Golgi or activated. The sterol-mediated inhibition of SCAP 
binding to COPII proteins is enhanced by both INSIG1 and INSIG2 (Dong, Tang, & Chen, 2012). 
INSIGs are resident ER proteins that interact with both SCAP and HMGCR in a sterol-dependent 
manner. Binding of cholesterol to SCAP promotes the interaction between SCAP and INSIG, 
thereby retaining the SCAP/SREBP complex in the ER and preventing activation of SREBPs. 
Thus, INSIGs are negative regulators of SREBP function and it appears that INSIGs enhance the 
response to cholesterol by promoting the binding of cholesterol to SCAP.  
INSIG1 is the dominant isoform, however, both INSIG1 and INSIG2 block the 
translocation of the SCAP/SREBP complex in response to sterols (Joseph L. Goldstein et al., 
2006). INSIG1 is an SREBP target gene and the induction of INSIG1 mRNA in response to insulin 
treatment is an indirect effect of the insulin-dependent induction of the SREBP1c gene, related 
to lipid synthesis (Guo, Bell, Mischel, & Chakravarti, 2014). Thus, SREBP induces the expression 
of its own negative regulator. INSIG2 is expressed at low levels, is not regulated by SREBPs and 
it is stable. By contrast, INSIG1 is rapidly degraded by the ubiquitin-proteasome system (UPS) 
in sterol-depleted cells (Gong, Lee, Lee, et al., 2006; Gong, Lee, Brown, Goldstein, & Ye, 2006; 
J. N. Lee, Gong, Zhang, & Ye, 2006). The ubiquitination and degradation of INSIG1 is negatively 
regulated by sterols, since INSIG-1 is stabilized when bound to the SCAP/SREBP complex in the 
presence of cholesterol (Gong, Lee, Lee, et al., 2006). When the levels of cholesterol decline, 
SCAP/SREBP detaches from INSIG1 and exits the ER. As a result, INSIG1 is rapidly ubiquitinated 
and degraded through the action of gp78, a membrane bound ubiquitin ligase (J. N. Lee, Song, 
DeBose-Boyd, & Ye, 2006). Thus, to block the activation of SREBPs, cells need to replenish their 
supply of both sterols and INSIG1 and both these processes are dependent on the 
transcriptional activity of SREBPs (Joseph L. Goldstein et al., 2006; Gong, Lee, Lee, et al., 2006). 
This type of regulation, which has been termed convergent inhibition, makes the system less 
dependent on cholesterol and ensures that active SREBP molecules have entered the nucleus 
and turned on their target genes. 
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Cholesterol metabolism is also regulated at the post-transcriptional level by various 
mechanisms including the degradation and phosphorylation of HMGCR, proprotein convertase 
subtilisin/kexin type 9 (PCSK9) dependent degradation of the LDL-R and the inducible degrader 
of the LDL receptor (IDOL) dependent ubiquitination of the LDL receptor. The HMGCR protein 
displays a long half-life, thereby maximizing mevalonate production for sterol and isoprenoid 
synthesis (Joseph L. Goldstein & Brown, 1990). Products from both pathways (sterols and 
isoprenoids) feedback to control HMGCR activity including the degradation of the enzyme 
(Joseph L. Goldstein et al., 2006). Although it has been known for some time that products of 
the mevalonate pathway control,  a key discovery was the finding that the sterol 
intermediates, lanosterol and 24,25-dihydrolanosterol, rather than the end product 
cholesterol, stimulate HMGCR degradation (Song, Javitt, & DeBose-Boyd, 2005). Lanosterol is 
the first sterol synthesized from mevalonate flux into the sterol pathway and its accumulation 
stimulates binding of the HMGCR to INSIG, resulting in the ubiquitination of HMGCR on two 
cytosolic lysine residues and subsequent degradation by the 26S proteasome. In addition to 
lanosterol, oxysterols promote the ubiquitination and degradation of the HMGCR (Song & 
DeBose-Boyd, 2004). Although it remains to be determined, oxysterols are presumably acting 
through their ability to bind INSIG and to stimulate INGIG binding to HMGCR. High 
concentrations of mevalonate are required for the rapid degradation of HMGCR. In addition to 
lanosterol, the complete and rapid degradation of HMGCR requires additional non-sterol 
isoprenoid signaling (Sever et al., 2003a). The requirement for this signal can be filled by 
addition of geranylgeraniol, a 20-C isoprenyl alcohol, but not the 15-C alcohol farnesol (Sever 
et al., 2003b). It is not known, however, which geranylgeraniol-derived metabolite is acting to 
control the HMGCR degradation. In addition to the degradation of HMGCR, it has recently 
been shown that cholesterol accelerates the proteosomal degradation of SM, the enzyme that 
catalyzes the first oxygenation step in cholesterol synthesis (Gill, Stevenson, Kristiana, & 
Brown, 2011). Unlike HMGCR, SM degradation is not mediated by INSIG, 24,25-
didydrolanosterol, or side-chain oxysterols, but rather by cholesterol itself. This finding 
suggests an additional control point in cholesterol metabolism beyond HMGCR. 
In addition, two additional players involved in the regulation of SREBP have recently 
been identified, erlins-1 and -2. Erlins-1 and -2 interact with the INSIG/SCAP/SREBP complex in 
fact, cholesterol directly binds to erlins-1 and -2. Huber et al. demonstrated that siRNA 
knockdown of erlins-1 and -2 continued to activate the SREBP pathway even in conditions of 
sterol excess, suggesting they play a role in restricting SREBP activation. Moreover, Insig, Scap, 
SREBP1a and SREBP-2 all co-immunoprecipitated with erlin-2 and the associated erlin-1 when 
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cellular cholesterol levels were high, but not when they were depleted, with INSIG being the 
more proximal binding partner. Together, these data support the hypothesis that erlins -1 and 
-2 play an important role in the cholesterol-dependent ER retention of SCAP/SREBP in 
cholesterol-sufficient conditions, possibly acting as scaffolds for the INSIG/SCAP/SREBP 
complex to retain SREBP in the ER  or help in the formation of the necessary ER subdomain 
required to form the INSIG/SCAP/SREBP complex and/or promote the degradation of INSIG 
(Huber, Vesely, Datta, & Gerace, 2013). 
 
3.2.4.3. Cholesterol uptaking regulation 
From the cholesterol absorption point of view, any factor that changes the 
transportation of cholesterol from the intestinal lumen to the lymph can influence the 
efficiency of cholesterol absorption because intestinal cholesterol absorption is a multistep 
process. When dietary conditions are controlled, biliary factors may exert a major influence on 
the efficiency of cholesterol absorption, any changes in which may partly explain 
interindividual and interstrain differences in cholesterol absorption efficiency in humans and 
other animals (D. Q.-H. Wang, 2007). For example, hepatic output and pool size of biliary bile 
acids are markedly reduced in mice with homozygous disruption of the cholesterol 7α-
hydroxylase (CYP7A1) gene that encodes the key enzyme of the neutral pathway of bile acid 
synthesis (Schwarz, Russell, Dietschy, & Turley, 2001). As a result, the mice absorb only trace 
amounts of cholesterol because of bile acid deficiency in bile. Similarly, upon deletion of the 
sterol 27- hydroxylase (CYP27) gene, which encodes the main enzyme of the alternative 
pathway of bile acid synthesis, the knockout mice display significantly reduced bile acid 
synthesis and pool size. Consequently, intestinal cholesterol absorption decreases from 54% to 
4%, whereas fecal neutral sterol excretion increases 2.5-fold (J J Repa, Lund, et al., 2000). 
However, in both knockout strains, cholesterol absorption is restored by feeding a diet 
containing cholic acid (J J Repa, Lund, et al., 2000; Schwarz et al., 2001). The absorption of 
biliary cholesterol is affected by its physical chemistry, but it is quite unclear whether dietary 
cholesterol is absorbed to the same degree as biliary cholesterol  (van der Wulp et al., 2013).  
At cellular level, PCSK9 enhances the degradation of the LDL-R (Benjannet et al., 2004).  
A large number of genetic variants of PCSK9 that may modulate plasma cholesterol levels have 
been found either positively or negatively. The PCSK9 gene is 25-kb long and comprises 12 
exons and 11 introns. It encodes a 692-amino acid serine protease formerly called neural 
apoptosis regulated convertase-1 (NARC1), which is a member of the proprotein convertase 
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family of enzymes (Maxwell & Breslow, 2004). These convertases act as molecular scissors for 
tissue-specific processing of multiple precursor proteins. The catalytic domain of PCSK9 
contains the main binding structure of PCSK9 to the epidermal growth factor-like repeat 
domain (EGF-A) of the LDL-R. The major function of the heterodimeric pro-segment PCSK9 is to 
degrade the LDL-R intracellularly and extracellularly, thereby acting as a chaperone that binds 
to the LDL-R to promote its lysosomal degradation. The deletion of PCSK9 protein results in an 
increase in LDL-R and a significant lowering of LDL cholesterol. Notably, recent studies have 
reported that PCSK9 inhibition using antibodies reduces LDL cholesterol over 60% (Chan et al., 
2009).  
 
3.2.4.4. Cholesterol efflux 
Cholesterol removal is necessary for cholesterol homeostasis and serves to prevent 
cholesterol over-accumulation in cells. Because cells cannot degrade cholesterol, excess 
cholesterol must be removed and transported to the liver for reutilization and excretion in a 
process that is traditionally referred to as reverse cholesterol transport (RCT) (Glomset & 
Norum, 1973). HDL serves as the major acceptor for cellular cholesterol released from 
extrahepatic tissues, and is inversely correlated with the risk of atherosclerotic cardiovascular 
disease (Marina Cuchel & Rader, 2006). Excess cellular cholesterol is eliminated by diffusion 
mediated or apolipoprotein-mediated mechanisms (Oram & Yokoyama, 1996; Yokoyama, 
2000). During passive diffusion, the removal of cholesterol is mediated by the exchange of 
cholesterol between the cell membrane and HDL. Many factors are likely involved in this 
process, such as cholesterol compartments in the plasma membrane and HDL structure. The 
enzyme lecithin-cholesterol acyltransferase (LCAT) has been suggested to also participate in 
this process (Yokoyama, 2000). LCAT is found on the surface of lipoproteins such as HDL and 
converts free cholesterol into cholesterol esters by transferring fatty acids from 
phosphatidylcholine  to unesterified cholesterol (Norum, 2017). The cholesterol esters are 
then sequestered into the core of the lipoprotein and transported to the liver and 
steroidogenic tissues where they are selectively removed by the scavenger receptor class B 
type 1 (SRB1) (Ji et al., 1997). A large amount of CEs that are formed within HDL are also 
transferred to the triglyceride rich lipoprotein by the cholesteryl ester transfer protein (CETP). 
The remnants of this protein are converted to LDL and removed by the LDL receptor pathway 
or directly removed in the liver for excretion into bile (Linsel-Nitschke & Tall, 2005). Two ATP-
binding cassette transporters, ATPbinding cassette subfamily G member 5 (ABCG5) and ATP-
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binding cassette subfamily G member 8 (ABCG8), are half-transporters that function as 
heterodimers to mediate the excretion of cholesterol into bile (Berge et al., 2000). Mutations 
in either gene lead to sitosterolemia, a recessive disease that is characterized by increased 
cholesterol absorption and impaired biliary secretion (Yoo, 2016).  
Another mechanism for cholesterol removal is mediated mostly by apoA1 (the major 
apoprotein of HDL) and leads to the assembly of discoidal HDL along with phospholipids and 
cholesterol (S. Wang & Smith, 2014). ABCA1 initiates HDL formation in the liver and is the first 
step in RCT (Tall, Yvan-Charvet, Terasaka, Pagler, & Wang, 2008). Several mechanisms have 
been proposed to facilitate ABCA1-mediated cholesterol efflux to lipid-poor apoA1. In one 
mechanism, apoA1 forms complexes with phospholipids and cholesterol at the cell surface, 
and is subsequently internalized and targeted to intracellular compartments, while lipidation 
of apoA1 occurs as part of the retroendocytosis pathway (Neufeld et al., 2004). In another 
mechanism, apoA1 forms complexes with phospholipids and cholesterol at the plasma 
membrane, this process is also mediated by ABCA1 (Nandi et al., 2009). The last mechanism is 
bases in a small pool of apoA1 binds to ABCA1, enhancing net phospholipid translocation and 
thus, membrane strain (Vedhachalam et al., 2007). The membrane strain is relieved by the 
bending and creation of exovesiculated lipid domains, which promotes the binding of apoA1. 
In addition to apoA1, this lipid transport pathway has broad specificity for multiple 
exchangeable apolipoproteins including apolipoprotein A2, apolipoprotein E, apolipoprotein  C 
and apolipoprotein  A4 (Remaley et al., 2001). While ABCA1 is the predominant factor needed 
for cholesterol efflux to apoA1 and the formation of pre-b HDL, other factors, such as LCAT, 
and the ABC transporters, ABCG1 and ATP-binding cassette subfamily G  member 4 (ABCG4), 
are needed for the maturation of HDL (van der Velde, 2010). After pre-b HDL is formed it must 
undergo further lipidation. Moreover ABCA1 and ABCG1 and ABCG1/ ABCG4 heterodimers 
synergistically mediate cholesterol efflux to HDL (Gelissen et al., 2006), however, the 
mechanism by which these transporters promote cholesterol efflux remains to be determined.  
One of the main regulator of the cholesterol efflux are the Liver X Receptor proteins 
(LXRs) which also contribute to cholesterol homeostasis. The LXRs, LXRa and LXRb, are nuclear 
receptors that form heterodimers with retinoid X receptors (RXRs) and are activated by a 
variety of sterol metabolites (Willy et al., 1995). Whereas LXRb is expressed ubiquitously, LXRa 
is primarily expressed in the liver, adipose tissue, and macrophages and thus plays an 
important role in lipid metabolism (Joyce J. Repa & Mangelsdorf, 2000). LXRs activate the 
transcription of genes involved in cholesterol efflux, including ABCA1, ABCG1, and ABCG5/8. 
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When cholesterol levels surpass the biosynthetic rate, a feed-forward pathway is initiated that 
leads to the clearance of cholesterol. The binding of oxysterols to LXRs triggers a 
conformational change in the receptor that enhances interaction with co-activator proteins, 
thereby facilitating transcription of the aforementioned target genes and RCT (Tontonoz & 
Mangelsdorf, 2003). In vivo studies show that LXR-deficient mice accumulate sterols in their 
tissues and develop accelerated atherosclerosis (Bradley et al., 2007), whereas synthetic LXR 
agonists stimulate ABCA1 expression and reverse cholesterol transport (J J Repa, Turley, et al., 
2000). 
 
3.2.4.5. Other cholesterol regulation mechanisms 
In addition to classic regulatory mechanisms, miRNAs have also been shown to 
regulate the expression of key genes in cholesterol metabolism. miRNAs are small ( ~ 22 nt), 
single-stranded, non-coding RNAs that regulate gene expression post-transcriptionally. 
In the cholesterol regulation mechanisms have been identified miR-33a and miR-33b, 
intronic miRNAs located within the Srebp-2 and Srebp-1 genes, respectively (Rayner et al., 
2010). Metabolic stimuli that activate the expression of Srebp-2 and Srebp-1 lead to an 
increased expression of miR-33a and miR-33b, respectively, suggesting that both host genes 
and miRNAs are co-regulated. miR-33a targets genes involved in cholesterol trafficking, 
including ABCA1, ABCG1, and NPC1 (Gerin et al., 2010). Interestingly, ABCA1, a transporter 
responsible for the movement of cholesterol out of the cell, was among the top predicted 
target genes for miR-33a. miR-33a overexpression strongly represses ABCA1 expression and 
decreases cellular cholesterol efflux to apoA1. On the other hand, antagonism of endogenous 
miR-33 up-regulates ABCA1 expression in vitro and in vivo, and promotes cholesterol efflux to 
apoA1, further confirming the physiological effects of miR-33 (Najafi-Shoushtari et al., 2010). 
Together, these findings establish a reciprocal pathway in which, during sterol-poor conditions, 
miR-33a is coincidentally generated with SREBP2 and works to increase cellular cholesterol 
levels by down-regulating ABCA1 and ABCG1 and thus, limit cholesterol efflux. As mentioned 
above, ABCA1 plays a key role in regulating HDL biogenesis in vivo. Remarkably, antagonists of 
miR-33 in vivo using locked nucleic acid modified oligonucleotides, lentivirus, and adenovirus 
increase significantly the expression of ABCA1 in the liver and plasma HDL levels (Horie et al., 
2010). 
Finally,   IDOL is an E3 ubiquitin ligase (transcriptionally activated by LXR agonists) that 
triggers ubiquitination of the LDL-R on its cytoplasmatic domain, thereby targeting it for 
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degradation. Unlike the LDL-R and Pcsk9 genes, Idol is not regulated by SREBPs. IDOL 
knockdown in hepatocytes increases LDL-R protein levels and promotes LDL uptake (Zelcer, 
Hong, Boyadjian, & Tontonoz, 2009). Conversely, adenovirus-mediated expression of IDOL in 
mouse liver promotes LDL-R degradation and elevates plasma LDL levels. Interestingly, IDOL 
targets two closely related LDL-R family members, VLDLR and apoE receptor 2 (ApoER2), two 
proteins implicated in both neuronal development and lipid metabolism. IDOL triggers 
ubiquitination of the VLDLR and ApoER2 on their cytoplasmic tails, leading to their degradation 




Related with the overaccumulation of cholesterol (Table 3) are cardiovascular diseases 
(CVD) which lead the cause of mortality worldwide, accounting for 16.7 million deaths each 
year (Thomas et al., 2018), about one third of total global deaths. Atherosclerosis, an 
inflammatory disorder of the vasculature, is the primary cause of CVD-related events, including 
myocardial infarction and stroke (Badimón, Vilahur, & Padró, 2009). Given the increase in 
prevalence of obesity and diabetes in developing countries, the global incidence of CVD is 
predicted to increase and impose a greater economic burden on the health-care services 
around the world. Under normal healthy conditions, the metabolism and transport of 
cholesterol, including influx and efflux within cells, is highly regulated. The development of 
atherosclerosis (Figure 6) can begin when these homeostatic mechanisms become unbalanced 
in favor of either increased cholesterol influx or decreased efflux. Within the blood, there are 
several lipoproteins that each has a different function in lipid transportation.  
LDL is one of the most important lipoproteins found in the bloodstream and its 
function is to transport cholesterol from the liver to the peripheral tissues (McLaren, Michael, 
Ashlin, & Ramji, 2011). In order to maintain a balance in cholesterol metabolism, HDL 
transports excess cholesterol from the peripheral tissues back to the liver for excretion via the 
bile system by a process known as reverse cholesterol transport. However, only 5% of the 
biliary cholesterol is excreted in feces as the rest is reabsorbed in the intestine (McLaren et al., 
2011). Given that high LDL-cholesterol and low HDL-cholesterol levels have been associated 
with reduced endothelial function, increased LDL-cholesterol and HDL-cholesterol levels are 
thought to be pro-atherogenic and anti-atherogenic, respectively (Vogel, 1997). Therefore, 
strategies for treating atherosclerosis should be aimed at lowering plasma LDL levels and 











Figure 6. The development of atherosclerosis. 
The expression of pro-inflammatory genes, 
including ICAM-1 and MCP-1, is triggered by the 
build-up of modified LDL in the neighbor 
endothelial cells during the development of the 
initial lesion. Circulating monocytes are then 
recruited to the modified LDL accumulation and 
migrate into the intima and differentiate into 
macrophages. Once in the walls of the artery, 
the macrophages are able to take up the 
modified LDL and become lipid-laden foam 
cells, which can accumulate and form a fatty 
streak. During complex lesion formation, foam 
cell lysis by apoptosis and necrosis leads to the 
formation of a necrotic core, and together with 
defective efferocytosis, leads to the 
amplification of the inflammatory response. 
SMCs begin to migrate from the media to the 
intima and the ECM produced by them forms 
fibrous cap and stabilizes the plaque. SMCs also 
transform to foam cells. During later stages of 
the complex lesion the plaque can become 
unstable owing to the inflammatory response, 
resulting in an inhibition of ECM formation, 
particularly collagen production by SMCs. The 
remaining ECM can then start to be degraded 
by proteases released by macrophages, 
resulting in an unstable lesion that can rupture 
and lead to thrombosis. These events can cause 
a myocardial infarction or stroke, depending on 
the location of plaque formation. 
ECM, Extracelular matrix; ICAM-1, Intercellular 
adhesion molecule-1; LDL, Low density lipoprotein; 
MCP-1, Macrophage chemoattractant protein-1; 




The first stage of atherosclerosis is the internalization of cholesterol via circulating LDL 
in the intima, with the concomitant endothelial activation/ dysfunction. The vascular 
endothelium is a semipermeable barrier that controls the diffusion of plasma molecules and 
regulates vascular tone, inflammation and prevents thrombus formation (Komarova, Kruse, 
Mehta, & Malik, 2017), properties that are lost with the dysfunctional endothelium. 
Consequently, LDL particles further infiltrate and accumulate in the extracellular matrix (ECM); 
circulating monocytes are then recruited and attached to the vascular endothelium due to the 
exposure to endothelial adhesion molecules. Once attached, they transmigrate into the sub 
endothelial space where they are transformed into macrophages. Moreover, injury in the 
endothelial-related antithrombotic properties facilitates platelet adhesion and activation in the 
dysfunctional area. Adhered platelets, in arrangement with dysfunctional endothelial cells, 
secrete chemotactic and growth factors, which stimulate migration, accumulation and 
proliferation of vascular smooth muscle cells (VSMC)  and leukocytes in the intimal layer, 
promoting plaque progression (Jennings, 2009). 
LDLs retained in the ECM mainly by proteoglycans become targets for oxidative and 
enzymatic modifications. Oxidized LDLs (oxLDLs) enhance a series of pro-inflammatory 
reactions via different mediators perpetuating the activation, recruitment and transmigration 
of monocytes and other inflammatory cells across the endothelial layer into the intima. In 
addition, the attracted macrophages scavenge oxLDLs, become lipid laden, and convert into 
foam cells. In the early steps of atherosclerosis, accumulation of foam cells evolves into fatty 
streaks. Complication of the lesion occurs when foam cells release growth factors and 
cytokines, which further stimulate VSMC migration from the media into the intima where they 
divide and produce ECM components such as collagen and contribute to the formation of a 
fibrous cap.  
If the pathological process persists and macrophages fail to remove accumulated 
cholesterol from the vessel, they become apoptotic, releasing cholesterol to the vessel wall 
and, more importantly, pro-thrombotic molecules and metalloproteinases (Ghosh, Zhao, Bie, & 
Song, 2010). Progression and complication of atherosclerotic plaques are also characterized by 
a decreased number of VSMCs as well as the formation of immature and leaky new vessels, 
making atherosclerotic lesions more susceptible to rupture. Plaque disruption and the 
subsequent exposure of thrombogenic substrates initiate both platelet adhesion/activation 
and aggregation on the exposed vascular surface and the activation of the coagulation 
cascade, leading to thrombus formation and clinical manifestations of the atherosclerotic 
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disease, acute myocardial infarction or sudden death (Legein, Temmerman, Biessen, & 
Lutgens, 2013).  
A large part of the anti-atherogenic and anti-thrombotic properties of the vascular 
endothelium are mediated by its capacity to produce and release substances such as nitric 
oxide (NO), a platelet aggregation inhibitor with a strong vasodilatory activity and an 
important antiinflammatory function. NO blocks the expression of proinflammatory molecules 
such as necrosis factor kappa B (NF-kB) and adhesion molecules such as intracellular adhesion 
molecule 1 (ICAM1) and vascular cell adhesion molecule 1 (VCAM1) as well as leukocyte 
infiltration and adhesion. Tight and gap junctions are cell-cell connections with essential 
structures in regulating the endothelial permeability function. The formation of gap junctions 
is regulated by the presence and functionality of connexins, proteins whose expression is 
altered during the formation of atherosclerotic lesions. Gap junctions favor intercellular 
signaling processes and regulate NO-dependent vasodilation (Badimón et al., 2009). 
Atherogenic concentrations of LDL lead to a decrease in the bioavailability of endothelial NO. 
This decrease in NO availability is associated with a reduction in the concentration and/or 
activation of the endothelial NO synthase (eNOS), as a result of the presence of native LDL or 
modified LDL particles, as well as the degradation of NO through the formation of superoxide 
anions (O2-). The imbalance between the redox state and NO is associated with protein 
nitrosylation. Deactivation of NO by O2- gives rise to highly cytotoxic peroxynitrite radicals. The 
increase of peroxynitrites derived from nitrotyrosines and the production of O2- are 
characteristics present in human atherosclerotic lesions (Pritchard et al., 1995). 
 It has been demonstrated that increased formation of reactive oxygen species (ROS) 
and/or altered oxygen utilization contributes to atherogenesis by superoxide production that 
mediates endothelial dysfunction and increases oxLDL levels. Small oxidized lipids that are 
components of oxLDL, such as oxysterols, oxidized fatty acids and aldehydes, are potent 
inducers of ROS production (Littlewood & Bennett, 2003). ROS in the vascular wall are 
generated by enzymes such as NADPH oxidase, xanthine oxidase and eNOS. Formation of 
intracellular ROS in the mitochondrial electron transport chain is controlled by antioxidant 
mechanisms. It has been shown that the increase of ROS generation by the mitochondria 
triggers cytochrome C release leading to caspase activation and apoptosis. The generation of 
large amounts of ROS can overwhelm the intracellular antioxidant defense, causing activation 
of neutrophils, protein modification, lipid peroxidation, and DNA damage, key factors for the 
initiation of atherosclerosis and the development of CVD. 
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Although excess cholesterol in blood is related with atherosclerosis, the exact causes 
and risk factors are unknown; however, certain conditions, traits, or habits may raise the 
chance of developing atherosclerosis. Most risk factors including high total cholesterol and LDL 
cholesterol (LDL-C), low level of HDL in blood, hypertension, tobacco smoke, diabetes mellitus, 
obesity and sedentary lifestyle can be controlled and atherosclerosis can be delayed or 
prevented. Across cultures there are many different dietary lifestyles, some of which promote 
health and others that increase risk of atherosclerosis (Torres, Guevara-Cruz, Velázquez-





















3.4. Familial hypercholesterolemia 
Familial hypercholesterolemia (FH) is among the commonest inherited metabolic 
disorders. It is caused due to a group of genetic disorders that result in abnormally high LDL 
cholesterol (LDL-C) levels that cause premature atherosclerotic plaque deposition in arteries 
and a markedly increased risk of CVD at a young age. The inheritance was first described in the 
1960s with an autosomal codominant inheritance with homozygotes having twice the LDL-C 




The frequency of the heterozygous FH state has been estimated at 1 in 500 and of the 
homozygous FH state at 1 in 1.000.000 (M. Cuchel et al., 2014). Initial prevalence estimates for 
heterozygous FH were based on the relatives of the survivors of myocardial infarction (J L 
Goldstein, Schrott, Hazzard, Bierman, & Motulsky, 1973). Higher heterozygous frequencies 
ranging from 1:67 to nearly 1:400 have been reported in certain populations. In these 
population groups, it is hypothesized that genetic drift led to the expansion of genotypes 
established by a few probands (founder effect) (Bétard et al., 1992). The recent investigation 
of an unselected community-based population of nearly 69.000 individuals in Denmark has 
suggested that the prevalence of heterozygous definite or suspected FH may be as high as 1 in 
137 (Benn, Watts, Tybjaerg-Hansen, & Nordestgaard, 2012). It follows that the prevalence of 
homozygous FH may be as high as 1 in 160.000 in this population. It is important to remember 
that most prevalence estimates cited in the literature are based on clinical and not genetic 
criteria. Patients with FH predominantly have an excess of CVD rather than cerebral or 
peripheral arterial disease. The risk of premature CVD is elevated to about 20-fold in 
heterozygous FH, with the highest risk being noted in young untreated men (Watts, Lewis, & 
Sullivan, 2007) . Patients with homozygous FH typically develop CVD by the second decade of 
life. CHD deaths in the first decade of life have been reported as well. Cases of valvular and 
supravalvular aortic stenosis due to lipid deposition have been reported with homozygous FH 
and rarely with heterozygous FH (Ozumi et al., 2005). Systematic data evaluating the 
prevalence of FH in most countries/territories are lacking. The majority of patients with FH are 





In most cases, FH has dominant or co-dominant inheritance with over 90 % penetrance 
(J L Goldstein & Brown, 1979). Mutations in LDL-R, apoB, LDLRAP1, and PCSK9 genes between 
others have been linked to FH (Table 2). Known variants in these genes have been found in 
over 80 % of patients with FH. Heterozygous FH is caused by a pathogenic variant in one allele. 
In contrast, homozygous FH results from either biallelic mutations in one of the known genes 
(true homozygotes) or compound heterozygosity for two different mutations in the same or 
different candidate genes known to cause FH. 
Mutations in LDL-R were identified as a cause of FH in the 1970s and are seen in >80 % 
of patients with FH (J L Goldstein & Brown, 1974b). The gene for LDL-R lies on the short arm of 
chromosome 19 (19p13.1– 13.3). Defects noted in the LDL-R can be classified into five broad 
categories: defective ligand binding, defective transport, defective internalization, recycling, 
and complete lack of receptors (Soutar & Naoumova, 2007). At present, >1600 mutations have 
been identified that can be consulted in the University College London Low Density Lipoprotein 
Familial Hypercholesterolemia Database. The pathophysiology of the LDL receptor is the 
following: 
1. Decreased LDL receptor function due to a genetic defect, typically one of the following 
classes: 
- LDL-R is not synthesized. 
- LDL-R is not properly transported from the ER to the Golgi apparatus 
for expression on the cell surface. 
- LDL-R does not properly bind LDL on the cell surface. 
- LDL-R does not properly cluster in clathrin-coated pits for receptor 
endocytosis. 
- LDL-R is not recycled back to the cell surface. 
2. LDL-R -mediated endocytosis is decreased. 
3. Leading to markedly elevated LDL levels 





Table 2. Known mutations in familial hypercholesterolemia. 
Mutation Gene Mechanism Number of mutations (% 
of FH cases) 
Inheritance 
LDL receptor LDL-R LDL receptor is 
absent or has 
decreased capacity 
to clear LDL from 
circulation 




ApoB Impaired LDL 
receptor binding-
mutation at binding 
site on LDL particle 
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PCSK9 gain of 
function 
PCSK9 Increased PCSK9 
level leads to 
increased 






Apoliprotein E ApoE Impaired LDL 
receptor binding-
mutation at binding 







adaptor protein 1 

































apoB is present on the LDL particle surface and serves as the ligand for the LDL-R. 
Mutations in apoB (chromosome 2p23–24) have been identified in about 2–5 % of cases in 
northern Europe but have not been commonly noted in other populations. The APOB mutation 
that has been most commonly detected among northern Europeans is Arg35000Gln 
(haplotype inherited from a common ancestor 6000–7000 years ago) (Myant, Forbes, Day, & 
Gallagher, 1997). Another substitution at the same codon-Arg3500Trp has been noted in the 
Chinese population (Tai, Pan, & Lee-Chen, 1998). Apo B mutations have been reported as 
having variable penetrance. 
 PCSK9 spans codes for a protein that serves as a post-transcription inhibitor of LDL-R 
by cell-surface interaction (to induce LDL-R degradation). Mutations leading to “gain” of 
function of PCSK9 activity account for < double heterozygote < homozygous APOB or PCSK9 
gain-of-function mutation < homozygous LDLRAP1 or LDL-R defective mutations < compound 
heterozygote: LDL-R defective plus LDL-R-negative (null) mutation < homozygous LDL-R-
negative (null) mutation (M. Cuchel et al., 2014).  
Very rarely, mutations in other genes involved in lipoprotein metabolism can cause FH. 
DNA sequencing efforts in individuals with FH in whom no mutations in LDL-R, ApoB or PCSK9 
could be detected found dominant mutations in ApoE (apolipoprotein E) and STAP1 (signal-
transducing adaptor protein 1), but these cases remain exceedingly rare (Awan et al., 2013; 
Fouchier et al., 2014). In a few families in which the severe FH phenotype segregates as a 
recessive trait, genetic mapping studies have identified causative homozygous mutations in 
LDLRAP1 (Fellin, Arca, Zuliani, Calandra, & Bertolini, 2015). Individuals with LDLRAP1 mutations 
are diagnosed clinically with severe hypercholesterolemia and usually also receive a genetic 
diagnosis of homozygous FH. Their phenotype is generally less severe than that of patients 
with homozygous FH due to LDL-R mutations (M. Cuchel et al., 2014) . Next-generation DNA 
sequencing analyses of patients with severe hypercholesterolemia and apparently recessive 
inheritance of this phenotype have also identified rare mutations on both alleles of other 
genes that have been associated with dyslipidaemia, namely, ABCG5, ABCG8 and lysosomal 
acid lipase (LIPA) (Stitziel et al., 2013).  
Mutations in ABCG5 or ABCG8 can cause sitosterolemia (an extremely rare condition in 
which plant sterols accumulate in the blood and tissues) and mutations in LIPA can cause 
lysosomal acid lipase deficiency (cholesterol ester storage disease or Wolman disease) 
(Fouchier & Defesche, 2013; Patel, 2014). Such findings suggest that mutations in genes that 
have been linked to other syndromic lipid disorders can also rarely cause high LDL cholesterol 
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levels and should be considered in individuals with apparent FH but without mutations in the 
most common causative genes. 
Occasionally, patients carry more than two mutations in genes associated with FH (M. 
Cuchel et al., 2014) . However, depending on the LDL-C threshold used for diagnosis, in at least 
20–40% of patients with possible or probable heterozygous FH by clinical criteria, no causative 
mutation in any gene associated with FH (Talmud et al., 2013). Although it remains possible 
that these patients might carry a mutation in a gene known to cause FH but that the tests did 
not detect the mutation or — less probably — that a mutation occurred in a new causative 
gene, a large proportion of these patients instead have a severe form of polygenic 
hypercholesterolemia (Talmud et al., 2013). 
 In the general population, there are numerous common single nucleotide 
polymorphisms (SNPs) in a variety of genes that have been associated with LDL-C levels in 
large-scale genome-wide association studies (Willer et al., 2013). Each of these SNP loci slightly 
raises or decreases LDL-C by an incremental amount. The distribution of these independently 
segregating small-effect SNP alleles is such that most individuals carry a balance of LDL 
cholesterol-raising and LDL cholesterol-lowering alleles. However, individuals at the high 
extreme of this distribution have inherited a preponderance of LDL cholesterol-raising alleles 
that cumulatively can raise LDL cholesterol into the range observed in patients with 
heterozygous FH due to large-effect single-gene mutations (Willer et al., 2013). At present, 
there is no clinical standard for which precise loci and alleles should be included in a genetic 
risk score (Jian Wang et al., 2016). Clinically, if these patients have elevated LDL-C and a family 
history of dyslipidemia or CVD, for all practical purposes they can be diagnosed with FH. SNPs 
and polygenic contribution to lipid levels may also mostly account for variable penetrance 
noted in families, besides environmental factors, dietary influences, gene-environment 
interactions, epigenetic influences, and random variation (Ferrières, Lambert, Lussier-Cacan, & 
Davignon, 1995). This may also explain milder phenotypes rarely seen with severe mutations. 







Although the atherosclerotic manifestations of FH usually occur in adulthood, the 
clinical effects of the disease can start in the first decade of life in homozygous patients (M. 
Cuchel et al., 2014). Unfortunately, FH is often diagnosed late and after the occurrence of a 
major coronary event. A combination of screening methods to identify at risk individuals is 
needed to prevent premature atherosclerosis (Goldberg et al., 2011). 
Patients with heterozygous FH are generally asymptomatic in childhood and early 
adulthood. About 5% of heart attacks under the age 60 and as many as 20% under age 45 are 
due to FH (Hopkins, Toth, Ballantyne, Rader, & National Lipid Association Expert Panel on 
Familial Hypercholesterolemia, 2011). Homozygous or compound heterozygous FH has a 
severe and variable clinical presentation usually within the first decade of life. Most of these 
individuals have extreme hypercholesterolemia with rapidly accelerated atherosclerosis when 
left untreated. The variation depends of the amount of LDL-R activity (Raal & Santos, 2012a). 
Coronary artery disease is the most common cause of premature death in these patients, but 
other cardiovascular disease including aortic and supravalvular aortic stenosis and aortic root 
disease is also common. 
There are a number of barriers to the diagnosis and treatment of FH. Many individuals 
and family members with FH who have CVD have other common CVD risk factors; thus genetic 
hypercholesterolemia is not suspected and ultimately not diagnosed. Primary care physicians 
manage most patients with hypercholesterolemia, and there is often a lack of awareness of FH 
among physicians and the general public with only very severe cases being referred to 
specialists (Watts et al., 2014).  
Cascade screening, in which health care providers actively screen for disease among 
the first and second degree relatives of patients diagnosed with FH, can increase detection 
rates but risks missing affected individuals. There are guidelines recommending universal 
screening for elevated serum cholesterol by age 20 and cascade testing of first-degree relatives 
of all individuals with FH (Watts et al., 2011). For children, cholesterol screening should be 
done at age 9 to 11 and considered beginning at age 2 in those with a family history of 
premature cardiovascular disease or elevated cholesterol (Daniels, Gidding, de Ferranti, & 
National Lipid Association Expert Panel on Familial Hypercholesterolemia, 2011).  
Overall, diagnosis of FH is based on lipid levels (Table 3), family history, physical 
findings (if present), and genetic analysis. Physical examination findings of tendon xanthomas, 
arcus corneae (under age 45) and tuberous xanthomas or xanthelasma (under age 25) when 
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present at an early age should also prompt suspicion for FH. However, physical findings are not 
present in all patients with FH (Hopkins et al., 2011).Taken together, the general clinical 
approach to consider FH is the following: 
1. Presence of premature atherosclerotic cardiovascular disease 
2. Fasting LDL-C levels >190 mg/dL in adults after exclusion of secondary causes of 
elevated LDL-C (hypothyroidism, nephrotic syndrome). 
3. Fasting untreated LDL-C levels that have an 80% probability of FH in the general 
population: 
- ≥250mg/dL in adults ≥ 30 years. 
- ≥ 220mg/dL in adults aged 20 to 29. 
- ≥ 190mg/dL in patients under age 20. 
4. Presence of full corneal arcus under age 45. 
5. Presence of tendon xanthomas. 
6. Family history of premature atherosclerotic cardiovascular disease. 
7. Family history of high cholesterol levels. 
On the other hand, the diagnosis of homozygous (or compound heterozygous) FH  has 
been defined in a number of ways (Raal & Santos, 2012a), with one possible definition in the 
next list: 
1. Genetic analysis showing mutations in two alleles at gene locus for LDL-R, APOB, 
PCKS9, LDLRAP1 or related. 
2. Presence of untreated LDL >500 mg/dL or treated LDL > 300 mg/dL plus one of the 
next parameters: 
- Presence of cutaneous or tendon xanthomas before the age of 10 years. 
- Both parents with evidence of heterozygous FH (except for the rare LDLRAP1 
mutations). 
Clinical criteria may not identify all patients with FH, and genetic testing is part of 
screening strategies in a number of countries, with the costs covered by national health 
services (Nordestgaard et al., 2013). Genetic testing in certain populations has changed 
understanding of the frequency of both heterozygous and homozygous FH as mentioned 
previously. However, a mutation is not always found in patients with clinical FH, and lack of a 





Table 3. Average blood cholesterol level recommendations. Based on the USA Cholesterol Guidelines. 
These data can vary depending on age and sex. 
 Desirable (mg/dl) Caution (mg/dl) Dangerous (mg/dl) 
Total Cholesterol <200 200-239 >240 
LDL-C <130 130-159 >160 
HDL-C >50 40-49 <40 
Triglycerides <200 200-399 >400 
 
3.4.4. Treatments 
The lifetime risk of CVD and premature onset CVD is very high in individuals with FH. Early 
treatment is beneficial and long term drug therapy can substantially reduce or eliminate the 
added lifetime risk of CVD from having FH and can lower the CVD event rate in heterozygous 
FH patients to levels similar to those of the general population (Versmissen et al., 2008). 
However, the first steps to treat FH is by life style changes as follows: 
1. Dietary modification contributes to improvement in lipid profiles: 
- A heart healthy diet including vegetables, fruit, non-fat dairy, beans, tree nuts, 
fish and lean meats should be encouraged. 
- Restrict intake of saturated fat to less than 7% of calories. 
- Avoid trans fatty acids. 
- If alcohol is used, amount should be moderate. 
- Addition of plant stanols and insoluble fiber can provide some LDL-C lowering. 
- Dietitian counseling. 
2. Physical activity. 
3. Avoidance of weight gain. 
4. Avoidance and cessation of smoking is mandatory. 
5. Discourage exposure to passive smoking. 
6. Treat diabetes and hypertension. 
7. Consider low-dose aspirin. 
Homozygous patients require treatment as soon as the diagnosis is made and need 
lifestyle, medication and additional modalities. Treatment of homozygous FH patients can 
delay major cardiovascular events and early death (Raal et al., 2011).  
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Figure 7. Structural formulas of statin inhibitors and the enzyme substrate HMG-CoA. Structure of 
several statin inhibitors. Compactin and simvastatin are examples of type 1 statins; not shown are the 
other type 1 statins, lovastatin and pravastatin. Fluvastatin, cerivastatin, atorvastatin, and rosuvastatin 
are type 2 statins. The HMG-like moiety that is conserved in all statins is colored in red. The IC50 (median 
inhibitory concentration) values of the statins are indicated. Structure of HMG-CoA. The HMG-moiety is 
colored in red, and the Km value (Enzyme affinity) of HMG-CoA is indicated. Adapted from (Istvan & 
Deisenhofer, 2001). 
HMG-CoA, 3-Hydroxy-3-Methyl-Glutaryl Coenzyme A 
3.4.4.1. Statins 
The most effective oral agents for the prevention and treatment of cardiovascular diseases 
associated to dyslipidemia are the statins (Figure 7). Statins, inhibitors of the HMGCR, are 
molecules of fungal origin. By inhibiting a key step in the sterol biosynthetic pathway statins 
are powerful cholesterol lowering medications. 
All statins can reduce LDL cholesterol in FH, and the absolute reductions achieved in 
heterozygous FH often exceed those observed in the general population, because of the higher 
baseline LDL cholesterol in patients (Besseling, Hovingh, Huijgen, Kastelein, & Hutten, 2016). 
By contrast, the response to statins in patients with homozygous FH is attenuated compared 
with that of the general population (Robinson, Goldberg, & National Lipid Association Expert 
Panel on Familial Hypercholesterolemia, 2011). For the same reason, high-potency statins are 
preferred, owing to their superior efficacy. Statins reduce CVD risk in both homozygous and 
heterozygous FH (Raal et al., 2011). Statins are generally well tolerated by patients, although 
doses are higher than those usually prescribed (Cupido, Reeskamp, & Kastelein, 2017). 
Statins should be the initial drug for all adults with FH and in children with heterozygous 
FH starting at 8 to 10 years of age (Ito, McGowan, Moriarty, & National Lipid Association 
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Expert Panel on Familial Hypercholesterolemia, 2011). Patients with homozygous FH should be 
treated as soon as the diagnosis is made (Raal & Santos, 2012b). The Food and Drug 
Administration (FDA) has approved lovastatin, atorvastatin, simvastatin and rosuvastatin 
children above 10 years of age and pravastatin in those over 8 years. Statins increase the 
expression of LDL receptors by reducing HMGCR, the rate-limiting step in cholesterol synthesis. 
Moderate to high potency statins should be used as first line treatment (atorvastatin, 
rosuvastatin, simvastatin, pitavastatin). Low potency statins are usually inadequate for FH 
patients (Watts et al., 2014). Adult FH patients should have a treatment goal of ≥ 50% LDLC 
reduction from baseline. Statin therapy is effective in heterozygous FH patients and may also 
benefit homozygous patients who have some LDL receptor activity (M. Cuchel et al., 2014).  
Long-term safety of statins in the pediatric population is still unknown, but the current 
benefits of therapy outweigh the risk of untreated pediatric populations (Daniels et al., 2011). 
Children and adolescents being treated with statins should have regular follow up with close 
monitoring of creatinine kinase (CK), aspartate amino transferase (AST) and alanine amino 
transferase (ALT) levels. Baseline levels, then repeat testing should be done at 1-3 months 
after drug initiation and then yearly. If CK levels reach five times and AST or ALT three times 
the upper limit of normal, a 3-month drug-free holiday should be initiated with reintroduction 
of the same drug at a lower dose or a different statin if levels return to baseline (Varghese, 
2014). Additionally, high lipoprotein (a) (A similar form of LDL from which it differs due to the 
presence of apolipoprotein (a) bound to apoB via one disulfide bridge) levels were recently 
found to be an independent risk factor for CVD among asymptomatic statin-treated FH 
patients (Vuorio, Watts, & Kovanen, 2019). 
Patients with FH who have a higher risk of CVD require more intensive drug therapy. High-
risk patients include those with: 
1. Clinically evident CVD. 
2. Diabetes. 
3. Family history of very early CVD (<45years in men and <55 years in women). 
4. Current smoking. 
5. Two or more CVD risk factors. 
6. High lipoprotein (a) (≥ 50mg/dL). 




3.4.4.1.1. Statins side effects 
Approximately 25% of the world population older than 65 years take a statin for primary or 
secondary prevention of cardiovascular diseases (Gu, Paulose-Ram, Burt, & Kit, 2014). 
Although statins are generally well tolerated, patients treated with statins may complain of 
diminished lower extremity muscular strength (Loenneke & Loprinzi, 2018). Moreover, statins 
may produce statin-induced myotoxicity (SIM), including heterogeneous clinical manifestations 
such as muscle weakness, muscle pain or aching (myalgia), stiffness, muscle tenderness, 
cramps, and arthralgia. Any of these symptoms can be presented with or without an elevation 
of CK serum concentrations released from muscles in response to exercise, which can signal 
skeletal muscle injury in rare cases (Smit, Bär, Geerdink, & Erkelens, 1995). On the contrary, 
elevation of serum CK might be the only sign of SIM. 
 Statin intolerance occurs in 10–15% of patients with FH  (Stroes et al., 2015). The 
management of statin intolerance in these patients is similar to that in other groups with high 
CVD risk and includes statin re-challenge (that is, the reintroduction of a statin after 
suspending the treatment for ≥4 weeks, during which time symptoms abate), switching to a 
different statin, reducing statin doses or increasing dosing intervals and use of combination 
treatment with non-statin agents (Mancini et al., 2016). 
Also liver toxicity from statins is often a fact, it is not common, and serious hepatotoxicity 
is extremely rare. Hepatic aminotransferase elevation is usually mild and does not require 
discontinuation of the statin. It may be dose dependent. Only about 1% of patients have 
aminotransferase increases to greater than 3 times the upper limit of normal, and the 
elevation often decreases even if patients continue on the statin. A common cause is hepatic 
steatosis, which responds to weight loss. Statins can be used cautiously in the presence of liver 
disease as long as it is not decompensated (Herrick, Litvin, & Goldberg, 2014). In particular, 
nonalcoholic fatty liver disease is not a contraindication. Hepatic transaminases should be 
obtained at baseline and during treatment if there is a clinical indication for their 
measurement. Irreversible liver damage resulting from statins is extremely rare, with a liver 
failure rate of 1 case per 1 million person-years of use (Cohen, Anania, Chalasani, & National 
Lipid Association Statin Safety Task Force Liver Expert Panel, 2006). 
However, even in the presence of statin intolerance symptoms, LDL-C reduction should be 
maximized and prioritized in patients with FH (Wiegman et al., 2015). Women should interrupt 
or be cautioned about continuing statin treatment during pregnancy and breastfeeding, owing 
to concerns over teratogenicity (Amundsen et al., 2006).  
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3.4.4.2. Non-statin drugs 
In most patients with FH, statins alone are insufficient to normalize LDL-C levels, and 
ezetimibe and PCSK9 inhibitors should be added to control LDL-C levels more effectively.  In 
some cases, the addition of ezetimibe to a statin is the preferred approach in the treatment of 
patients with FH (Watts et al., 2014). Some patients may require three or more medications to 
lower LDL-C adequately. 
Fibrates are a class of amphipathic carboxylic acids. They are used for a range of metabolic 
disorders, mostly for triglyceride lowering but may have some LDL-C lowering effect. 
Ezetimibe, niacin, and bile acid sequestrants are also treatment options for drug intensification 
or for those intolerant of a statin. This should also be considered in FH patients who are not at 
very high risk when LDL-C does not decrease by 50% with statin monotherapy. It is important 
to note that doubling the dose of statin only achieves an additional LDL reduction by 6 -7% 
(Jones et al., 2003). Other options for those intolerant of statins include every other day statin 
therapy or lowering the dose while adding other treatment medications. 
Ezetimibe is localized at the brush border of the small intestine and inhibits the absorption 
of cholesterol. It reduces LDL-C by about 15 to 20% when used alone and provides 20% 
percent additional reduction in combination with statins (Gagné, Gaudet, Bruckert, & 
Ezetimibe Study Group, 2002). 
Bile acid sequestrants inhibit the enterohepatic reuptake and increase fecal loss of bile 
salts. They decrease LDL-C by preventing the reabsorption of bile acids in the terminal ileum. 
Because they are not absorbed systemically, they are considered safer to use then other 
cholesterol-lowering medications (Insull, 2006). Like ezetimibe, the effect on LDL-C reduction 
can be additive with statins and even ezetimibe (Huijgen et al., 2010). The need for 
suspensions or large numbers of pills, gastrointestinal side effects, and multiple drug-drug 
interactions limits patient adherence and use. Colesevelam, as compared to other bile acid 
sequestrants, has fewer gastrointestinal side effects and drug-drug interactions. Colesevelam 
is also approved for treatment of diabetes and may help patients achieve both glycemic and 
lipid goals (Zieve, Kalin, Schwartz, Jones, & Bailey, 2007).  
Niacin, a water-soluble B vitamin, lowers LDL-C and raises HDL. It comes in crystalline and 
extended release forms. Due to concerns for liver toxicity, most non-prescription sustained 
release forms are not recommended (Ito et al., 2011). 
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 PCSK9 inhibitors deliver a dose-dependent LDL cholesterol reduction of 50–65% in 
patients with FH  and enable most patients to reach LDL cholesterol levels and prevention 
targets comparable to those of the general population (Qian et al., 2017). Data shows that 
PCSK9 inhibitors to statin treatment further reduces CVD events in high-risk patients with 
persistent inadequately controlled LDL cholesterol levels (Sabatine et al., 2017).  
Lomitapide is an oral inhibitor of MTTP, which is required for the assembly and secretion 
of lipoproteins that contain apoB, in conjunction with mipomersen which is an antisense 
oligonucleotide that binds to APOB mRNA and inhibits its translation, thereby reducing apoB 
synthesis and secretion are alternatives for patients who remain refractory to standard 
pharmacological treatments, especially patients with homozygous FH (Santos et al., 2016). In 
fact, lomitapide and mipomersen are only formally approved by the FDA for patients with 
homozygous FH, owing to their high cost and high rates of adverse effects, including 
















3.4.4.3. Non pharmacological treatments 
LDL apheresis is an important treatment modality for homozygous FH patients and for 
heterozygous patients who have not met treatment goals despite optimal tolerated medical 
therapy (Raal et al., 2011). It is an extracorporeal treatment that uses various methods to 
remove LDL from the circulation. LDL apheresis is currently FDA approved and has been shown 
in clinical trials to prevent and slow the progression of CHD (G. R. Thompson et al., 2010). 
LDL apheresis is recommended for the following patients: 
1. LDL goal reduction has not been achieved despite diet and maximum drug therapy 
(after 6 months). 
2. Adequate drug therapy is not tolerated or contraindicated. 
3. Functional homozygous FH patients with LDL-C ≥ 300mg/DL (or non-HDL cholesterol ≥ 
330 mg/dL). 
4. Functional heterozygous FH patients with LDL-C ≥ 300 mg/dL (or non-HDL ≥ 330 
mg/dL). 
5. Functional heterozygous FH patients with LDL-C ≥ 200 mg/dL (or non – HDL cholesterol 
≥ 230 mg/dL) or high lipoprotein (a) ≥ 50 mg/dL. 
6. Functional heterozygotes with LDL cholesterol ≥ 160 mg/dL (or non-HDL cholesterol ≥ 
190 mg/dL) and established CVD, other cardiovascular disease or diabetes. 
Apheresis is generally done every 1 to 2 weeks with each session taking about 3 hours and 
removing greater than 60% of Apo-B containing lipoproteins (G. R. Thompson et al., 2010). The 
LDL reduction with LDL apheresis is temporary and associated with a rebound elevation in lipid 
levels after the procedure. The efficacy of LDL apheresis can be enhanced by the addition of 
statin therapy. LDL apheresis treatment in homozygous FH patients has improved their life 
expectancy to over 50 years. Cost and limited availability decrease widespread use of LDL 
apheresis. 
For patients who do not achieve lipid goal reduction by the above modalities, other 
potential treatment options include partial ileal bypass and liver transplantation. Liver 
transplantation produces a significant lowering of LDL-C by providing normal LDL receptors. 
Nowadays, liver transplantation is used primarily in children with homozygous FH when 
apheresis is not an option or with concurrent heart transplantation (Palacio, Harring, Nguyen, 
Goss, & O’Mahony, 2011).  Its use, however, is limited due to risk of transplant surgery and the 
limited number of donor livers. Partial ileal bypass is rarely used and works by interrupting 
enterohepatic bile acid circulation. 
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3.4.4.4. New approaches 
Because interfering with PCSK9 function effectively reduces LDL cholesterol levels and CVD 
events, PCSK9 has become a target for lipid-lowering therapy using antibody-based drugs. 
Other approaches, such as gene silencing by RNA interference and antisense oligonucleotides, 
have been developed to interfere with PCSK9 production (Turner & Stein, 2015). The 
compound inclisiran, a long-acting small interfering RNA inhibitor of PCSK9 synthesis, was 
studied in 501 patients in a phase II study (Kausik K. Ray et al., 2017). Dose-dependent 
reductions in LDL cholesterol were observed at 6 months: reductions of 28–42% after a single 
dose of inclisiran and 36–53% after two doses. The two-dose inclisiran regimen reduced LDL 
cholesterol in 48% of the patients, and LDL cholesterol remained reduced compared with its 
baseline level after 8 months. Adverse events occurred slightly more often with inclisiran than 
with placebo (11% and 8%, respectively) (Kausik K. Ray et al., 2017). Antisense oligonucleotides 
are currently under development for other molecular targets, including for the inhibition of 
angiopoietin-related protein 3 (ANGPTL3, whose main function seems to be the regulation of 
lipoprotein lipase), MTTP and Lipoprotein (a) particles (Cupido et al., 2017).  
Adnectins are fusion proteins derived from the tenth type III domain of human fibronectin 
and can bind to target proteins with high affinity and specificity. BMS962476, a PCSK9-targeted 
adnectin conjugated to polyethylene glycol, reduced LDL cholesterol by 48% and PCSK9 levels 
by >90% after subcutaneous injection in a phase I study (Turner & Stein, 2015). Additionally, in 
preclinical studies, peptide-based anti-PCSK9 vaccines showed a reduction of LDL cholesterol 
up to 55% for 1 year. In mouse models, these vaccines induced the generation of PCSK9 -
specific antibodies that efficiently blocked murine PCSK9, upregulated murine LDL-R 
expression and recognized human PCSK9 (Galabova et al., 2014). 
 Numerous other LDL cholesterol-lowering agents are at various stages of development 
and might be available in the future for the management of at least some patients with 
heterozygous or homozygous FH, including the mentioned lomitapide and mipomersen as well 
as evinacumab (an antibody against ANGPTL3), bempedoic acid (an inhibitor of ATP citrate 
synthase, which is involved in the synthesis of acetyl-CoA and cholesterol) and gemcabene 
(which increases VLDL clearance) (Gryn & Hegele, 2016). Addition of daily oral anacetrapib, a 
CETP inhibitor, to baseline statin therapy over 4 years reduced well-controlled LDL cholesterol 
by 17% and CVD events by ~9% (REVEAL Collaborative Group et al., 2017). Whether these 
results are applicable to patients with FH is uncertain, but CETP inhibitors now represent a 
third category of non-statin agents (in addition to ezetimibe and PCSK9 inhibitors) that, when 
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added to a statin regimen, further reduce LDL cholesterol and CVD events in secondary 
prevention in the general population.  
The ultimate cure for FH could be corrective gene therapy or gene replacement therapy, 
and although such potentially definitive treatments remain elusive, there are several 
promising investigational agents. An adeno-associated virus (AAV) vector encoding LDL-R cDNA 
induced a significant reduction of hypercholesterolemia in a humanized mouse model, which 
was Ldlr-null with transgenic expression of APOBEC, which encodes the catalytic component of 
the ApoB mRNA-editing enzyme complex. After injection of a low dose of the AAV vector 
containing LDL-R, the animals expressed human LDL-R and ApoB (Somanathan et al., 2014). 
Similarly, transfection with a vector expressing a gain of function LDL-R variant that is resistant 
to degradation by human PCSK9 and IDOL further reduced LDL cholesterol levels in mice 
(Kassim et al., 2013). If even one of these promising leads can be translated into a safe, 



















We have mentioned what is cholesterol, how it is regulated and what are 
consequences of its accumulation by a pathological disorder as FH. However, if we look at the 
literature there are plenty studies about FH at organism level, but if we look closer and wonder 
“What about the cell?” There is almost no bibliography. Does the lack of cholesterol 
absorption affect the cell in any way? Theoretically the answer is no because cells can 
synthetize its own cholesterol as it is explained above. However, in practice, there are only a 
few papers which give some hints about what is going on in the cell of FH patients. As 
Descartes said “Divide each difficulty into as many parts as is feasible and necessary to resolve 
it”, maybe with a molecular point of view of FH we could not only learn more about FH but 
find new possible treatments far from the actual trends. 
 The initial objective of this thesis is to verify several molecular parameters of the FH 
related to the mutation in the LDL-R in patient fibroblasts in order to find new possible 
treatments. These will include levels, metabolism and synthesis of cholesterol, mitochondrial 
function, inflammation, autophagy and apoptosis. Due to the high relevance of this pathology 
in the large vessels, we will create an endothelium cell model by silencing the LDL-R and try to 
mimic the phenotype in this cell type. In this way, it can be corroborated and if the disease 
affects fibroblasts and endothelial cells in the same way. Because of the correlation between 
cholesterol and CoQ10 biosynthesis, CoQ10 pathways and regulation will be also studied. 
The usage of human fibroblasts as cellular model in FH was previously corroborated by 
the experts of the cholesterol metabolism research Brown and Goldstein. In fact, they were 
given the Medicine Nobel Prize in 1985 using this model (Brown & Goldstein, 1996). 
Once the necessary markers to complete a molecular analysis of the pathology have 
been obtained, an adequate treatment that reverses the symptoms and produces a beneficial 








The distribution of the study will be the following: 
1. Controls and four FH patient fibroblast characterization: 
a. General lipids and cholesterol accumulation observation by fluorescence 
(Filipin), Oil Red O staining and electron microscopy. 
b. LDL-R levels by immunofluorescence and immunoblotting. 
c. LDL uptake by fluorescent LDL. 
d. Cholesterol and CoQ10 biosynthesis by radioactive mevalonate assay. 
e. Expression levels of biosynthesis and regulation related proteins by 
immunoblotting and qPCR. 
f. Mitochondrial characterization: 
1. Reactive oxygen species production by flow cytometry. 
2. Mitochondrial membrane potential (ΔΨm) by flow 
cytometry. 
3. ATP production and bioenergetic profile by SeaHorse 
assay. 
4. Mitophagy activation by immunofluorescence and 
immunoblotting. 
5. Mitochondrial mass by flow cytometry, immunoblotting 
and spectrometry. 
g. Autophagic flux by immunofluorescence and immunoblotting. 
h. Cholesterol and CoQ10 levels by HPLC. 
i. De novo cholesterol and CoQ10 biosynthesis by TLC chromatography. 
j. Inflammation factors by immunoblotting and ELISA. 
2. Generate and characterize an endothelial cell model: 
a. Generate an endothelial FH cell model by LDL-R lentiviral silencing. 
b. Characterizing the endothelial cell model: 
1. LDL uptake by fluorescent LDL. 
2. Expression levels of biosynthesis and regulation related 
proteins by immunoblotting. 
3. Cholesterol accumulation by fluorescence (Filipin). 
4. Membrane potential by flow cytometry. 
3. Develop an adequate treatment for FH based on affected cells parameters and 
stablish its effects on patient cells by the same methods of point “1. Controls and 
four FH patient fibroblast characterization.” 
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5. Material and Methods 
 
5.1. Reagents 
Monoclonal anti-actin antibody, anti-VDAC1/Porin and anti-BECLIN1, rotenone, 
antimycin A and oligomycin were obtained from Sigma-Aldrich (St. Louis, MO). Monoclonal 
antibodies against complex III (core 1 subunit), complex I (30 kDa subunit) and Complex IV (Cox 
II subunit), SREBP-2,  RCAS (Golgi marker), polyclonal antibodies against INSIG2, NRLP3 and 
SCAP,  MitoSox Red, CMH2-DCFDA, 10-N-nonyl acridine orange (NAO), LysoTracker, 
tetramethylrhodamine methyl ester (TMRM), Fluorescent LDL Conjugates (DiI LDL) and 
Hoechst 33342 were obtained from Thermo Fisher Scientific/ Invitrogen/Molecular Probes 
(Waltham, MA). Anti-cytochrome c and anti-caspase 3 antibodies were obtained from BD 
Biosciences Pharmingen (San Jose, CA). Anti-GAPDH (Glyceraldehyde 3-phosphate 
dehydrogenase) monoclonal antibody (clone 6 C5) was from Calbiochem-Merck Chemicals Ltd. 
(Nottingham, UK). Anti-hATG12-ATG5 was obtained from Biosensis (South Australia, Australia). 
Anti-MAP-LC3 (N-20), anti-catalase (H-300), anti-PDI (H-160), anti-Golgi marker (AE-6), anti-
cathepsin B, HMGCR, anti LDL-R, anti-caspase 1, anti-AMPK, anti-AMPK-p, anti-PPAR, anti-
SREBP-1, anti-squalene synthase, anti-lanosterol synthase, anti-COQ1, anti-COQ2, anti-COQ7, 
anti-PCSK9, anti-ABCA1, anti-INSIG1, LDL-R shRNA and scramble shRNA were obtained from 
Santa Cruz Biotechnology (Santa Cruz, CA). Protease inhibitors were obtained from Boehringer 
Mannheim (Indianapolis, IN). All other chemicals were purchased from Sigma-Aldrich. Gap, PA, 
USA). 2-[14C]-(R, S)-mevalonate (55 mCi/mmol) was purchased from Amersham 
(Buckinghamshire, UK). 
All PBS (Phosphate Buffer Saline) used were 1x and pH 7.4, diluted from PBS 10x 
obtained from Intron Biotechnology. 
 
5.2. Ethical statements 
Approval of the ethical committee of the Hospital Universitario Virgen Macarena y 
Virgen de Rocío de Sevilla (Spain) was obtained, according to the principles of the Declaration 





5.3. Fibroblasts cultures 
Cultured fibroblasts were derived from a skin biopsy of patients (P1, P2, P3 and P4) 
with FH harboring heterozygous null mutations at the LDL-R gene: 
 P1: carries the mutation c.1197_1205delCTACCTCTT 
  P2 and P3: non-related patients with the same mutation, a deletion from exon 9 
to exon 12, c.1187-? _1845+? del. 
  P4: carries the mutation c.12G>A, p. (Trp4*). 
 Control fibroblasts were human skin primary fibroblasts from healthy volunteers. 
Samples from patients and controls were obtained according to the Helsinki Declarations of 
1964, as revised in 2001. Fibroblasts from FH patients and controls were cultured at 37°C in 
DMEM (Dulbecco’s Modified Eagle Medium) containing 4.5 g·L−1 glucose, L-glutamine, and 
pyruvate supplemented with 1% antibiotic solution and 20% Fetal Bovine Serum (FBS). 
 
5.4. LDL-R silencing cells 
Endothelial cells (EA.hy926) were a generous donation from Carmelo Bernabeu 
Quirante (Centro Investigaciones Biológicas, CIB, Madrid, Spain). Cells were seeded in two 12-
wells plates, silenced control and silenced LDL-R were grown in DMEM medium with 4,5 
g·L−1 glucose, 10% fetal bovine serum and 1% antibiotics (Optimal medium). After reaching a 
confluence of 50%, cells were washed once with PBS and replaced with optimal medium plus 
10 μg/ml of Polybrene (Santa Cruz Biotech). shRNA Lentiviral particles (Santa Cruz Biotech) 
were added to the culture (shControl/shLDLR) and incubated overnight. Cell were washed with 
PBS once and replaced with optimal medium and incubated overnight. Every well were split in 
3 different T25 Flasks and continue incubating for 48 hours in optimal medium. To select 
transfected and stable clones, the medium was supplemented with 0.5 μg/ml puromycin 






5.5. LDL uptake 
The fluorescent-labeled LDL uptake assay was performed according to manufacturer's 
instructions (Thermo Fisher Scientific/Invitrogen/Molecular Probes). Cultured fibroblasts were 
incubated 2 hours at 37ºC with culture medium mixed with human fluorescent LDL complexes 
at 12 μg/mL. After incubation, cells were rinsed twice with culture medium and visualized in 
vivo using an upright fluorescence microscope (Leica DMRE, Leica Microsystems GmbH, 
Wetzlar, Germany). 
5.6. Oil red O staining 
Oil red-O staining was performed as previously described (MCVEAN, PATRICK, & 
WITCHETT, 1965). Fibroblasts were grown on 1 mm width glass coverslips for 72 h in culture 
medium. Cells were rinsed twice with PBS, fixed in 3.8% paraformaldehyde for 5’ at room 
temperature, and permeabilized with 0.1% saponin for 5’. A 6:10 dilution was made from a 5% 
Oil red solution prepared in 2-propanol and added to cells for 60’ at room temperature. The 
staining solution was removed and cells were washed with PBS three times before viewing by 
optical microscopy. 
 
5.7. Filipin staining 
Filipin staining was performed as previously described (Behnke, Tranum-Jensen, & van 
Deurs, 1984). Fibroblasts were grown on 1 mm width glass coverslips for 72 h in normal 
growth medium. Cells were rinsed twice with PBS, fixed in 3.8% paraformaldehyde for 5’ at 
room temperature and rinsed again. Cells were incubated for 10’ at room temperature with 
1.5 mg glycine/ml PBS to quench the paraformaldehyde. A working solution of 0.05 mg/mL 
Filipin (Sigma-Aldrich) in PBS was prepared and added to fibroblasts for 2 hours at room 
temperature. Cells were rinsed twice with PBS and visualized by fluorescence microscopy using 
a UV filter set. Filipin staining was quantified by measuring fluorescence intensity using the 





5.8. Measurements of cholesterol and CoQ10 levels 
Cholesterol and CoQ10 levels in cultured fibroblasts were measured using a method 
previously described by our group (Rodríguez-Hernández et al., 2009; Tang, Miles, DeGrauw, 
Hershey, & Pesce, 2001). Fibroblast pellets were lysed with 500µL PBS 1x and mixed 
vigorously. Then, 20 µL of 30 µM Coenzyme Q9 was added as internal standard. 500µL SDS 2% 
and 2mL of ethanol:isopropanol (95:5) were added to each sample and mixed. To extract 
lipids, 4 ml of hexane were added and vortexed. Samples were centrifuged at 1000×g for 5’ at 
4 °C and the upper phase was recovered. This step was repeated twice and 12mL were dried 
via rotary evaporation. Lipid extracts were vortexed with 900µL of ethanol (HPLC quality) and 
dried in a speed-vac. The lipid pellet was suspended and homogenized in 100µL of ethanol 
prior to HPLC injection. Lipid components were separated by a SHIMADZU UFLC HPLC system 
equipped with a reversed-phase Shim-pack XR-ODS C-8 column in a column oven set to 40 °C, 
with a flow rate of 0.5 ml/minute and a mobile phase containing 80:20 methanol/2-propanol. 
Coenzyme Q9 (internal standard), CoQ10 and cholesterol levels were analyzed with a SPD-20A 
prominence UV-VIS detector at 200 and 245nm, respectively. 
 
5.9. De novo synthesis of cholesterol 
The rates of synthesis of cholesterol and CoQ10 were measured following  a protocol 
previously described (Nambudiri, Ranganathan, & Rudney, 1980). Fibroblast were incubated 
with 2-[14C]-(R, S) - mevalonolactone (55 mCi/mmol, Amersham, Buckinghamshire, UK) at a 
concentration of 10,000 dpm/mL and 20 μM unlabeled mevalonolactone (Sigma-Aldrich) in the 
media for 48h at 37°C and 5% CO2. Lipid extraction was developed as indicated previously. The 
resulting lipid extracts were complemented with 5 µg of cholesterol and CoQ10 and 
fractionated by thin layer chromatography (TLC) on 20x20 cm silica gel plates Si60 (Merck 
Millipore, Darmstadt, Germany) activated for 1h at 100°C. The mobile phase was hexane/ethyl 
ether 80:20. The bands corresponding to cholesterol and CoQ10 were located by exposing the 
plate to iodine vapor, and the bands were scrapped off from the plates and the silica gel 
transferred to scintillation vials. The radioactivity incorporated in the bands was measured by 
liquid scintillation in a Beckman Coulter SL6500 counter and the rates of synthesis calculated 
attending to the specific radioactivity of the precursor.  
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5.10. Immunofluorescence microscopy 
Fibroblasts were grown on 1 mm width glass coverslips for 72 h in normal growth 
medium. Cells were rinsed twice with PBS, fixed in 3.8% paraformaldehyde for 5’ at room 
temperature, and permeabilized with 0.1% saponin for 5’. Glass coverslips were incubated at 
37ºC with primary antibodies diluted 1:100 in PBT for an hour and rinsed twice with PBS. The 
secondary antibody, diluted 1:100 in PBS, was incubated for 45’ at 37°C. The coverslips were 
then rinsed twice with PBS, incubated for 4’ with PBS containing Hoechst 33342 dilution 
1:1000 and washed with PBS. The coverslips were mounted onto microscope slides using 
Vectashield Mounting Medium and analyzed using an upright fluorescence microscope (Leica 
DMRE, Leica Microsystems GmbH, Wetzlar, Germany). Images were taken using a DeltaVision 




Western blotting was performed using standard methods. After transferring the 
proteins, the membranes were incubated with primary antibodies at 1:1000, overnight, rinsed 
twice and incubated again with the corresponding secondary antibody. Multiple blots were run 
and several proteins of interest were serially detected. Every membrane was checked for 
protein loading using Ponceau staining and actin expression levels. Stripping was not used. As 
possible each membrane was re-probed with different antibodies if the molecular weight of 
the protein did not interfere with the previous one. If the proteins were sufficiently separated 
from one another during gel electrophoresis, then membranes were cut and each respective 
piece was used to detect the appropriate protein. 
 
5.12. ATP levels 
An ATP determination kit (Invitrogen-Molecular Probes) was used to measure ATP 
levels by a bioluminescence assay. 
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5.13. Mitochondrial membrane potential 
FH fibroblasts were grown on multiwell plates for 24 to 48 hours, incubated with 100 
nM TMRM for 30’ and examined by flow cytometry. Treatment of control cells with 20 μM 
FCCP for 20’ was used as positive control of ΔΨm depolarization. 
 
5.14. Mitochondrial mass 
Mitochondrial mass was determined by flow cytometry after cell staining with 10 μM 
10-N-nonyl acridine orange (NAO) for 10’ at 37°C in the dark. Alternatively, mitochondrial mass 
was assessed measuring citrate synthase activity (Rustin et al., 1994) . 
 
5.15. Mitochondrial reactive oxygen species 
Mitochondrial ROS generation in fibroblasts was assessed by MitoSOX, a red 
mitochondrial superoxide indicator. Once in the mitochondria, MitoSOX red reagent is oxidized 
by superoxide and exhibits red fluorescence. Approximately 1 x 106 cells were incubated with 1 
μM MitoSox for 30’ at 37°C, washed twice with PBS, resuspended in 500 μl of PBS, and 
analyzed by flow cytometry (excitation at 510 nm and fluorescence detection at 580 nm). 
Specificity of MitoSOX for superoxide has been shown by the manufacturer, and its 
mitochondrial localization was tested by co-staining with MitoTracker Green (data not shown). 
ROS levels were expressed relative to the mitochondrial mass (ROS signal/NAO signal).  
 
5.16. Mitochondrial respiratory chain activity 
Activities of NADH cytochrome c reductase (complexes I+III) and citrate synthase were 
determined spectrophotometrically in sonicated and permeabilized fibroblasts using 
previously described methods (Rustin et al., 1994). Results are expressed as units/citrate 
synthase (mean±SD). Protein content was determined by the Lowry procedure.  
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5.17. Real-time quantitative PCR 
The fibroblast expression of ATG12, MAP-LC3, BECLIN1, COQ10 1, COQ10 2, SREBP-2, 
HMGCR and LSS (Lanosterol Synthase) genes in fibroblasts was analyzed by SYBR Green 
quantitative PCR using mRNA extracts and primers.  
 Human BECLIN1 primers 5-GGATGGATGTGGAGAAAGGCAAG-3 (forward) and 5-
TGAGGACACCCAAGCAAGACC-3 (reverse) amplify a sequence of 152 nt.  
 Human ATG12 primers 5-ATTGCTGCTGGAGGGGAAGG-3 (forward) and 5-
GGTTCGTGTTCGCTCTACTGC-3 (reverse) amplify a sequence of 198 nt.  
 Human MAP-LC3 primers 5-GCCTTCTTCCTGCTGGTGAAC-3 (forward) and 5-
AGCCGTCCTCGTCTTTCTCC-3 (reverse) amplify a sequence of 91 nt.   
 Human COQ1 primers 5-TTCAACAGCGACACCCACT-3 (forward) and 5- 
CTGCAATGGACTAGCTCTGC-3 (reverse) amplify a sequence of 179 nt. 
  Human COQ2 primers 5-CGCAGAGCCGTTGACTTAAG-3 (forward) and 5- 
GCGTTACTTGGATGGTCTGC-3 (reverse) amplify a sequence of 160 nt. 
  Human SREBP-2 primers 5-GGAGTGGTGCTGAATGTTGG-3 (forward) and 5-
TTTCTCCCACCTCAGTTCCC-3 (reverse) amplify a sequence of 132 nt. 
  Human HMGCR primers 5-CACAACAAGCTCCCATCACC-3 (forward) and 5- 
GGAAACTCATGAGCGTGGTG-3 (reverse) amplify a sequence of 127 nt.  
 Human LSS primers 5-CCCAACACAGTTCCTTCAGC-3 (forward) and 5-
TCTTCTGTCCAGCTCCCTTG-3 (reverse) amplify a sequence of 163 nt. 
  Human GAPDH primers 5- TTGAGGTCAATGAAGGGGTC -3 (forward) and 5- 
GAAGGTGAAGGTCGGAGTCA -3 (reverse) amplify a sequence of 185 nt. GAPDH was 








5.18. Electron microscopy 
Electron microscopy was performed as described (Rodríguez-Hernández et al., 2009). 
Culture cells were fixed with 2% glutaraldehyde for 15’ at RT and for 30’ in 2% glutaraldehyde 
0.1M NaCacodylate/HCl at pH 7.4. Fibroblasts were washed with 0.2 M NaCacodylate/ HCl, pH 
7.4 and fixed again for 30’ 1% OsO4- 0.15 M NaCacodylate/HCl, pH 7.4. Samples were 
dehydrated with ethanol at 30, 50, 70 and 95% for 5¡. Impregnation and inclusion steps were 
performed in Epon and polymerized for 48h at 60°C. An ultramicrotome RMC-MTX (Tucson, 
Arizona) was used to get 60-80 nm sections. Sections were contrasted with uranyl acetate and 
lead citrate. Philips CM-10 transmission electron microscope was used to capture images. 
 
5.19. Lysosomal content 
Fibroblasts were cultured in multiwell plates and incubated for 30’ at 37ºC with 100nM 
LisoTracker Red™ (Molecular Probes). After incubation, cells were washed and the red 
fluorescence was measured by flow cytometry. 
 
5.20. Interleukins 
IL-1β and IL-18 levels in culture mediums were assayed by commercial ELISA kits 
(MyBioSource, Inc., CA, USA). 
 
5.21. Bioenergetics 
Mitochondrial respiratory function of control and FH fibroblasts were measured using 
mito-stress test assay by XF24 extracellular flux analyzer (Seahorse Bioscience, Billerica, MA) 
according to manufacturer's instructions. Cells were seeded at a density of 3x104 cells/well in 
XF24 cell culture plates in 100 µL growth medium (DMEM medium containing 20% FBS) and 
placed in 37°C incubator with 5% CO2. After 24 h incubation, growth medium from each well 
were removed, leaving 50 µL of media. Then, cells were washed twice with 1,000 µL of pre-
warmed assay medium (XF base medium supplemented with 10 mM glucose, 1 mM glutamine 
and 1 mM sodium pyruvate; pH 7.4) and 450 µL of assay medium (500 µL final) was added. 
Cells were incubated in 37°C incubator without CO2 for 1 h to allow pre-equilibrating with the 
assay medium. Mitochondrial functionality was evaluated by sequential injection of four 
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compounds that affect bioenergetics. The final concentrations of injections were: 1 µM 
oligomycin, 2µM FCCP, 1 and 2.5 µM rotenone/antimycin A. The best concentration of each 
inhibitor and uncoupler, as well as the optimal cells seeding density were determined in 
preliminary analyses. A minimum of five wells per treatment were utilized in any given 
experiment. This assay allowed for an estimation of basal respiration, maximal respiration and 
spare respiratory capacity. 
 
5.22. Statistical analysis 
We used non-parametric statistics that do not have any distributional assumption, 
given the low reliability of normality testing for small sample sizes used in this work (Le 
Boedec, 2016). To compare parameters between groups, variables were evaluated using 
Wilcoxon match-paired signed rank test, Friedman Test or 2-way ANOVA Test. All results are 



















6.1. Cholesterol accumulation in fibroblasts derived from patients harboring LDL-R 
mutations 
In order to determine whether there was any evidence of defective LDL-R function in 
fibroblasts derived from FH patients, an in vitro LDL uptake assay was performed. Fluorescent 
labeled LDL complexes were used to evaluate the incorporation of cholesterol mediated by 
LDL-R in control and patient fibroblasts. All patient fibroblasts showed, as expected, a decrease 
of 60±10% of LDL uptake compared to control fibroblasts (Figure 8 A and B). Decreased LDL 
uptake was associated with reduced expression levels of LDL-R in FH fibroblasts assessed by 
Western blotting (Figure 8 C and D) and immunofluorescence microscopy (Figure 9).  
 Given that FH fibroblasts showed decrease LDL-C uptake, we next examined 
intracellular lipids in control and patient fibroblasts by oil red staining, a lysochrome commonly 
used to stain neutral lipids including esterified cholesterol. A significant increase in oil red 
staining was found in patient fibroblasts (Figure 8 E and F). Intracellular lipid accumulation was 
confirmed by electron microscopy examination that showed the presence of lipid droplets 
inside patient fibroblasts (Figure 8 G and H). To characterize lipid accumulation, cells were also 
stained with Filipin, a highly fluorescent polyene macrolide antibiotic which binds specifically 
to unesterified cholesterol but not to esterified sterols. Filipin staining was notably increased in 
patient fibroblasts indicating increased cholesterol content in patient cells (Figure 8 I and J). 
Mevalonate pathway is an important metabolic pathway which plays a key role in 
multiple cellular processes by synthesizing sterol isoprenoids, such as cholesterol, and non-
sterol isoprenoids, such as dolichol, heme-A, isopentenyl tRNA and CoQ10 (Buhaescu & 
Izzedine, 2007). It has been suggested that there is a relation between cholesterol and CoQ10 
levels due to the fact that both compounds are synthesized in the same pathway (Turunen, 





Figure 8. Impaired LDL uptake and cholesterol accumulation in FH fibroblasts. (A) Control and FH fibroblasts were 
incubated with a fluorescently-labeled LDL and examined by fluorescence microscopy. An impaired LDL-uptake was 
found in FH fibroblasts. Scale bar =15 μm. (B) Quantification of LDL-uptake by Image-J software. (C) LDL-R expression. 
Expression levels of LDL-R in control and FH fibroblasts determined by Western blotting. Actin was used as a loading 
control. For control cells, data are a pool of 2 different control cell lines. (D) Quantification of LDL-R Western blotting by 
Image-J software. (E) Oil red staining in control and FH fibroblasts. Scale bar =15 μm. (F) Image analysis of oil red 
staining. (G) Electron Microscopy in control and FH fibroblasts. Red arrows indicate lipid droplets. Scale bar =1 μm. (H) 
Quantification of lipid droplets. (I) Filipin staining in control and FH fibroblasts. Cells were then examined under 
fluorescence microscopy. Scale bar =15 μm. (J) Filipin quantification by Image J software. Data represent the mean±SD 
of 3 separate experiments. *p<0.05 between control and FH fibroblasts. **p<0.01 between control and FH fibroblasts. 




Figure 9. Immunofluorescence of LDL-R. Control and FH fibroblasts were fixed and immunostained with 
anti-LDL-R and examined by fluorescence microscopy. Nuclei were revealed by Hoechst staining. Scale 
bar=15 μm. 
LDL-R, Low Density Lipoprotein Receptor; FH, Familial Hypercholesterolemia 
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To explore mevalonate pathway in FH fibroblasts, we decided to examine de novo 
synthesis of two of the main final product of this pathway, cholesterol and CoQ10. Radioactive 
labelled mevalonate was incorporated to cells and cholesterol and CoQ10 levels were examined 
by thin layer chromatography (TLC). The radioactivity incorporated in cholesterol was 
significantly increased (Figure 10 A) while the radioactivity incorporated in CoQ10 was 
significantly reduced in FH patients (Figure 10 B). These findings made us suspect that elevated 
cholesterol biosynthesis might have induced increased cholesterol levels and a secondary 
deficiency of CoQ10. To asses this hypothesis, cholesterol and CoQ10 levels were measured in 
control and FH fibroblasts by HPLC. Cholesterol levels were markedly increased (Figure 10 C) 
while CoQ10 levels were significantly reduced (Figure 10 D) in patient fibroblasts.  
To further examine the mechanism of dysregulated mevalonate pathway in FH, the 
expression levels of proteins involved in cholesterol and CoQ10biosynthesis regulation were 
analyzed by Western blotting. The mature form of transcription factor SREBP-2 and SREBP-1 
which regulates the protein expression of key enzymes involved in cholesterol and lipid 
biosynthesis were increased in FH fibroblasts (Figure 11 and Figure 12). Accordingly, the 
expression levels of HMGCR, lanosterol synthase and squalene synthase were upregulated. 
Concomitantly, FH fibroblasts showed reduced expression of proteins involved in CoQ10 
biosynthesis (COQ1, COQ2 and COQ7) (Figure 11, Figure 12 A and B). Correspondingly, these 
alterations of protein expression levels were accompanied by increased expression of 




Figure 10. Dysregulated mevalonate pathway and mitochondrial dysfunction in FH fibroblasts. A and B: 
Cholesterol (A) and CoQ10 (B) biosynthesis analysis in control and FH fibroblasts was performed 
incubating cells with radioactive mevalonate. For control cells, the data are the mean±SD for 
experiments conducted on 2 different control cell lines. (C) Cholesterol levels in control and FH 
fibroblasts. (D) CoQ10 levels in control and FH fibroblasts. (E) Mitochondrial enzymatic activities of 
complex I+III in control and FH fibroblasts. (F) ΔΨm was assessed by flow cytometry using TMRM. A clear 
decrease of ΔΨm was observed in FH fibroblasts. Treatment of control cells with 20 μM FCCP for 20’ was 
used as positive control of ΔΨm depolarization. (G) ATP levels in control and FH fibroblasts. A significant 
decrease of ATP levels was observed in FH fibroblasts. (H) Mitochondrial ROS levels in control and FH 
fibroblasts. Results are expressed as the ratio of MitoSOX signal to 10-N-nonyl acridine orange signal. For 
control cells, the data are the mean±SD for experiments conducted on 3 different control cell lines. Data 
represent the mean±SD of 3 separate experiments. *p<0.05 between control and FH fibroblasts. 
**p<0.01 between control and FH fibroblasts. A.U., arbitrary units. 
CoQ10, Coenzyme Q10; FH, Familial Hypercholesterolemia; ΔΨm, Mitochondrial membrane potential; TMRM, 
Tetramethylrhodamine; FCCP, Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone; ATP, Adenosin triphosphate; 






Figure 11. Expression levels of proteins involved in cholesterol. SREBP-2, HMGCR, lanosterol and 
squalene synthase and CoQ10 (COQ1, COQ2 and COQ7) biosynthesis in control and FH fibroblasts were 
analyzed by Western blotting. Actin was used as a loading control. 
SREBP-2, Sterol regulatory element-binding protein 2; HMGCR, 3-Hydroxy-3-Methylglutaryl-CoA Reductase; CoQ10, 








6.2. Mitochondrial dysfunction in FH fibroblasts 
CoQ10 is an essential component of the mitochondrial electron transport chain (ETC) by 
transferring reducing equivalents from complexes I and II to complex III (Crane, 2001). In order 
to find out if CoQ10 deficiency also affects mitochondrial function in FH fibroblasts, we 
measured the activities of mitochondrial respiratory chain enzymes. Complex I+III activity was 
significantly reduced in patient compared to control fibroblasts (Figure 10 E). As reduced 
mitochondrial complexes activity may lead to mitochondrial dysfunction, we next examined 
ΔΨm and mitochondrial ROS production. Figure 10 F shows that ΔΨm was reduced in patient 
fibroblasts. To asses if cellular bioenergetics was also affected in patient fibroblasts, 
intracellular ATP levels were also measured. A decrease of 45±13% was found in patient 
fibroblasts (Figure 10 G). In addition, mitochondrial ROS levels were significantly increased in 
FH fibroblasts (Figure 10 H). 
 
Figure 12. Cholesterogenic 
and coenzyme Q10 genes 
expression. A and B 
densitometry of Western 
blotting of Figure 11. (C) 
Expression levels of 
cholesterogenic and CoQ10 
biosynthetic transcripts. 
Expression levels of 
HMCGR, lanosterol 
synthase, SREBP-2, COQ1 
and COQ2 transcripts were 
performed by RT-PCR. 
Data represent the 
mean±SD of 3 separate 
experiments. *p<0.01 
between control and FH 
fibroblasts.  
A.U., arbitrary units; CoQ10, 
Coenzyme Q10; HMGCR, 3-
Hydroxy-3-Methylglutaryl-
CoA Reductase; SREBP-2, 
Sterol regulatory element-
binding protein 2; RT-PCR, 
Real Time Polymerase Chain 
Reaction; SD, Standard 




Figure 13. Increased expression of 
autophagic markers in FH fibroblasts. 
(A) Quantification of acidic vacuoles in 
control and FH fibroblasts by 
LysoTracker staining and flow 
cytometry analysis. (B) Increased 
expression of autophagic transcripts. 
Expression levels of BECLIN1, LC3 and 
ATG5 were performed by RT-PCR. (C) 
Increased expression of autophagic 
proteins. The expression levels of LC3-
I (upper band) and LC3-II (lower 
band), ATG12, BECLIN1 and cathepsin 
D were determined in the control and 
FH fibroblast cultures by Western 
blotting. The ATG12 band represents 
the ATG12-ATG5 conjugated form. 
Actin was used as a loading control. 
(D) Densitometric analysis of Western 
blottings. (E) Autophagy flux in FH 
fibroblasts. Determination of LC3-II 
levels in the presence and absence of 
bafilomycin A1 in control and FH 
fibroblasts. Control and FH fibroblasts 
were incubated with bafilomycin A1 
(100 nM for 12 h). Total cellular 
extracts were analyzed by 
immunoblotting with antibodies 
against LC3. Actin was used as a 
loading control. (F) Densitometry of 
Western blotting was performed 
using the ImageJ software. For control 
cells, the data are the mean±SD for 
experiments conducted on 3 different 
control cell lines. Data represent the 
mean±SD of 3 separate experiments. 
*p<0.05 between control and FH 
fibroblasts.  
FH, Familial Hypercholesterolemia; LC3, 
Microtubule-associated proteins 1A/1B 
light chain 3B; ATG5, Autophagy Related 
5; RT-PCR, Real Time Polymerase Chain 
Reaction; ATG12, Autophagy Related 12; 
A.U., Arbitrary Units; SD, Standard 
Deviation. 
6.3. Selective degradation of mitochondria in FH fibroblasts 
 As mitochondria dysfunction is often associated with mitophagy activation as a 
mechanism for the elimination of damaged mitochondria (Cotán et al., 2016; De la Mata et al., 
2012), we next evaluated the amount of acidic vacuoles and the expression levels of 
autophagy proteins. Acidic vacuoles were examined by LysoTracker red staining coupled to 
flow cytometry analysis. Higher lysosomal content was found in FH fibroblasts respect to 




 To asses that high lysosomal content were accompanied by activation of autophagic 
processes, mRNA levels and proteins connected to autophagy were examined. The expression 
of BECLIN1, LC3 and ATG5 genes determined by quantitative PCR displayed an increase in FH 
patients respect to control fibroblasts (Figure 13 B). The same pattern was found when protein 
levels of ATG5-12, LC3-I and LC3-II were examined by Western blot (Figure 13 C and D). 
Increased levels of cathepsin B (CATHEP B), a lysosomal protein, were also found increased in 
patient fibroblasts compared to control fibroblasts. 
 Next, autophagy flux was examined by treating control and FH fibroblast with 
bafilomycin A1, a vacuolar H+ ATPase inhibitor that prevents the fusion between 
autophagosomes and lysosomes (Yamamoto et al., 1998), and analyzing LC3-II expression 
levels by Western blotting. Control cells treated with bafilomycin showed increased LC3-II 
expression levels indicating that autophagy flux was normal (Figure 13 E and F). In contrast, 
the treatment with bafilomycin in mutant fibroblasts (P1 and P2) induced only a slight increase 
in LC3-II expression levels suggesting that autophagy flux was impaired in FH fibroblasts (Figure 
13 E and F). 
 To assess the selective elimination of mitochondria in FH cells, protein expression 
levels of mitochondrial proteins were examined. Expression levels of mitochondrial proteins, 
VDAC/porine, Complex I (30 kDA subunit) and complex IV (Cox II subunit) were markedly 
reduced in FH fibroblasts (Figure 14 A). In contrast, protein expression levels of markers of 
other organelles such as endoplasmic reticulum (PDI), Golgi apparatus (RCAS) and peroxisomes 
(catalase) were not affected in patient fibroblasts, suggesting that only mitochondria were 
selectively eliminated in FH fibroblasts (Figure 14 A and B). Reduced mitochondrial mass was 
also confirmed by measuring citrate synthase activity, a well-known marker of mitochondria 
abundance. Citrate synthase activity was dramatically reduced in patient fibroblasts, indicating 
extensive mitochondrial loss and/or impaired mitochondrial biogenesis (Figure 14 C).  
 Mitophagy was also assessed by immunofluorescence microscopy by the examination 
of co-localization of the autophagosome marker LC3 and the mitochondrial marker 
cytochrome c. High co-localization between mitochondria and autophagosomes markers was 





Figure 14. Mitophagy in FH fibroblasts. (A) Western blot analysis of mitochondrial (complex I, 30 kDa subunit; 
complex IV, COX II subunit; and VDAC/porin), Golgi (Golgi marker), endoplasmic reticulum (PDI), and peroxisome 
(catalase) proteins in control and FH fibroblasts. Actin was used as loading control. (B) Densitometry of Western 
blotting. (C) Mitochondrial mass was determined by determining citrate synthase activity. For control cells, the data 
are the mean±SD for experiments conducted on 3 different control cell lines. Data represent the mean±SD of 3 
separate experiments. *p<0.05 between control and FH fibroblasts.  
A.U., arbitrary units; VDAC, Voltage-dependent anion channels; PDI, Protein disulfide isomeras; FH, Familial Hypercholesterolemia; 




Figure 15. Autophagosome and mitochondria markers colocalization in FH fibroblasts. (A) Image 
analysis of LC3 and cytochrome c immunostaining in control and FH fibroblasts. Control and FH 
fibroblasts were fixed and immunostained with anti LC3 (autophagosome marker) and cytochrome c 
(mitochondrial marker) and examined by fluorescence microscopy. Nuclei were revealed by Hoechst 
staining. Scale bar=15 μm. (B) Quantification of LC3/cytochrome c puntacta in control and FH (n=100 
cells).  Data represent the mean±SD of 3 separate experiments. *p<0.01 between control and FH 
fibroblasts. 




6.4. Inflammasome activation in FH fibroblasts 
Recent data suggest that damaged mitochondria could induce inflammasome 
activation (Cordero et al., 2014; Gurung, Lukens, & Kanneganti, 2015). It has been described 
that NLRP3 (nacht Domain-, leucine-rich repeat-, and PYD-containing protein 3) is able to sense 
dysfunctional mitochondrion explaining the common association between mitochondrial 
damage and inflammatory diseases (Zhou, Yazdi, Menu, & Tschopp, 2011). Inflammation has 
also been described as a key process in the formation of the atherosclerotic plaque (Salminen, 





Figure 16. Inflammasome 
activation in FH fibroblasts. (A) 
Western blot analysis of NLRP3, 
caspase-1 and caspase 3 in 
control and FH fibroblasts. 
Actin was used as loading 
control. (B) Densitometric 
analysis of Western blottings. 
Data represent the mean±SD of 
three separate experiments. 
*p<0.01 between control and 
FH fibroblasts. ap<0.05 between 
apoptotic and control and FH 
cells. C: IL-1β and IL-18 levels in 
culture media of control and FH 
fibroblasts were determined by 
an ELISA assay. Data represent 
the mean±SD of three separate 
experiments. *p<0.01 between 
control and FH fibroblasts. A.U., 
arbitrary units. 
FH, Familial Hypercholesterolemia; 
NLRP3, nacht Domain-, leucine-rich 
repeat-, and PYD-containing 
protein 3 ; SD, Standard Deviation; 
IL, Interleukin; ELISA, Enzyme-
Linked Immuno Sorbent Assay; 




To assess inflammasome activation in patient fibroblasts, NLRP3 expression levels and 
Caspase-1 cleavage were analyzed by Western blotting as well as inflammatory cytokines 
levels, IL-1β and IL-18, were measured by ELISA (Sharma & Kanneganti, 2016). Increased 
expression levels of NLRP3 and caspase-1-cleavage were found in patient fibroblasts (Figure 16 
A and B) indicating inflammasome activation. Caspase-3 cleavage was also examined to rule 
out the possibility that inflammasome activation in FH fibroblasts was due to apoptosis 
activation. Furthermore, IL-1β and IL18 levels in culture medium were significantly higher in FH 
fibroblasts (Figure 16 C and D). 
 
6.5. Effect of CoQ10 on FH fibroblasts 
As FH fibroblasts showed a dysregulation of mevalonate pathway associated with 
increased cholesterol and reduced CoQ10 biosynthesis, we next examined the effect of CoQ10 
treatment on cholesterol levels and the expression levels of several key proteins regulating this 
pathway. To that end, P1 and P3 fibroblasts were treated for 72 hours with 25µM CoQ10 and 
intracellular cholesterol levels were quantified by both HPLC (Figure 17 A) and Filipin staining 
(Figure 17 B). Both determinations showed that cholesterol levels were significantly reduced in 
CoQ10-treated FH fibroblasts, suggesting that CoQ10 was able to correct mevalonate pathway. 
Furthermore, CoQ10 treatment reduced significantly cytochrome c/LC3-II puncta (Figure 17 C) 
indicating improvement of mitochondrial function. The beneficial effects of CoQ10 treatment 
on mutant cells bioenergetics was also confirmed using a mito-stress test assay using the XF24 
















Figure 17. CoQ10 treatment restores 
cholesterol levels and reduces 
mitophagy in FH fibroblasts. (A) 
Control and FH fibroblasts were 
treated with 25 μM CoQ10 for 72 
hours. Cholesterol levels in control 
and FH fibroblasts were determined 
by hexane extraction and HPLC 
separation. (B) Filipin staining in 
control and FH fibroblasts treated 
with CoQ10. (C) Quantification of 
puncta (LC3 and cytochrome c 
colocalization) in control and FH 
fibroblasts treated with CoQ10. 
Control and FH fibroblasts were fixed 
and immunostained with anti-LC3 
(autophagosome marker) and 
cytochrome c (mitochondrial marker) 
and examined by fluorescence 
microscopy. For control cells, the data 
are the mean±SD for experiments 
conducted on 2 different control cell 
lines. Data represent the mean±SD of 
3 separate experiments. *p<0.01 
between control and FH fibroblasts. 
#p<0.01between the presence and 
the absence of CoQ10 treatment. 
CoQ10, Coenzyme Q10; FH, Familial 
Hypercholesterolemia; HPLC, High 
Pressure Liquid Cromatography; LC3, 
Microtubule-associated proteins 1A/1B 
light chain 3B; SD, Standard Deviation 
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6.6. CoQ10 treatment restores altered pathways in FH fibroblasts 
 In order to explore the molecular mechanism underlying the beneficial effect of CoQ10, 
the expression levels of several proteins regulating the mevalonate pathways were examined 
in control and FH fibroblasts. CoQ10 treatment of patient fibroblasts induced AMPK (5' 
adenosine monophosphate-activated protein kinase) activation and increased PPAR-α 
(peroxisome proliferative activated receptor alpha) expression levels.  This was associated with 
the restoration of COQ1, COQ2, COQ7 expression levels (Figure 19 and Figure 20). 
Furthermore, CoQ10 treatment decreased the expression levels of SREBP-2 (mature form), 
HMGCR and cholesterogenic enzymes such as squalene and lanosterol synthase. In contrast, 
CoQ10 increased the expression levels of LDL-R and reduced the expression levels of PCSK9. 
Interestingly, CoQ10 treatment also increased markedly LDL uptake by FH fibroblasts (Figure 
21A and 21B). The beneficial effects of CoQ10 on LDL-R and COQ1 expression levels were dose 
dependent as is showed in Figure 21C. Moreover, the effect of CoQ10 treatment on essential 
proteins for cholesterol sensing such as INSIG1, INSIG2 and SCAP was also examined. 
Surprisingly, the expression levels of INSIG1 and INSIG2 were markedly reduced in FH 
fibroblasts (Figure 19 and Figure 20). Interestingly, the expression of  both INSIGs was 
notably upregulated after CoQ10 treatment. In contrast, SCAP expression levels were slightly 
increased in FH fibroblasts and they did not change significantly after CoQ10 treatment (Figure 
19 and Figure 20). 
To assess the role of AMPK activation in correcting mevalonate pathway under CoQ10 
treatment we examined the expression levels of essential regulatory proteins of this pathway 
in the presence or absence of compound C, a selective inhibitor of AMPK. The correction of the 
expression of mevalonate pathway enzymes by CoQ10 was prevented by AMPK inhibition 
(Figure 22 and Figure 23). Similarly, the effect of CoQ10 on the expression of LDL-R, PCSK9 and 
NLRP3 was blocked by compound C (Figure 22 and Figure 23). Taking together, these results 









Figure 18. Effects of CoQ10 treatment on cell bioenergetics. Basal (A) and maximal (B) respiration, Spare 
Respiratory capacity (C) and ATP production (D) were determined in control (C1) and FH fibroblasts (P1) by 
using the Seahorse analyzer. Control and FH fibroblasts were treated with 25 μM CoQ10 for 72 h. *p<0.01 
between Control and FH fibroblasts. #p<0.01 between untreated and treated FH fibroblasts. 




Figure 19. Effect of CoQ10 treatment on several pathways regulating mevalonate pathway.  Western blot 
analysis of SREBP-2 processing, AMPK activation, and expression levels of PPAR-α, HMGCR, lanosterol 
synthase, squalene synthase, COQ2, COQ7, NLRP3, LDL-R, PCSK9, ABCA1, INSIG1, INSIG2 and SCAP. 
Control and FH fibroblasts were treated with 25 μM CoQ10 for 72 hours.  A representative actin band is 
shown, although loading control was checked in every Western blotting.  
CoQ10, Coenzyme Q10; SREBP-2, Sterol regulatory element-binding protein 2; AMPK, AMP-activated protein kinase; 
PPAR- α, Peroxisome proliferator-activated receptors; HMGCR, 3-Hydroxy-3-Methylglutaryl-CoA Reductase; NLRP3, 
nacht Domain-, leucine-rich repeat-, and PYD-containing protein 3; PCSK9, Proprotein convertase subtilisin/kexin type 
9; LDL-R, Low Density Lipoprotein Receptor; ABCA1, ATP-binding cassette transport; INSIG, Insulin induced gene; 







Figure 20. Densitometric analysis of Western blotting of Figure 19. (A, B, C and D)  Data represent the 
mean±SD of three separate experiments. *p<0.05 between control and FH fibroblasts. #p<0.05 between 
the presence and the absence of CoQ10 treatment. 
SD, Standard Deviation; FH, Familial Hypercholesterolemia; A.U., arbitrary units; CoQ10, Coenzyme Q10 
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6.7. Cholesterol accumulation and mitochondrial dysfunction by silencing LDL-R in 
endothelial cells 
 
To reproduce the pathological alterations observed in patient fibroblasts, LDL-R was 
silenced by siRNA in human endothelial cells. As expected, LDL-R silencing in endothelial cells 
induced a marked reduction of LDL uptake ( 
Figure 21 A and B) accompanied by up-regulation of cholesterogenic enzymes such as 
HMCGR, lanosterol synthase and squalene synthase, and down-regulation of biosynthetic 
CoQ10 enzymes such as COQ1 ( 
Figure 21 C and D). LDL-R silencing also induced a marked down-regulation of INSIG1 
and INSIG2 expression levels as well as a significant increase of SCAP expression levels. 
Accordingly, LDL-R silenced cells presented cholesterol accumulation ( 
Figure 21 E), mitochondrial depolarization ( 
Figure 21 F) and inflammasome activation assessed by increased NLRP3 levels ( 





Figure 21. Effects of LDL-R silencing on human endothelial cells. (A) Control, control siRNA (SCRM), and LDL-
R silenced endothelial cells were incubated with a fluorescently-labeled LDL and examined by fluorescence 
microscopy as described in Material and Methods. An impaired LDL-uptake was found in LDL-R silenced 
endothelial cells. (B) Quantification LDL-uptake by Image-J software. (C) Western blot analysis of LDL-R, 
HMGCR, squalene synthase, lanosterol synthase, COQ1, mature SREBP-2, NLRP3, INSIG1, INSIG2 and SCAP in 
cell extracts from control, control siRNA (SCRM) and LDL-R silenced endothelial cells. Actin was used as 
loading control. (D) Densitometry of Western blotting. (E) Quantification of cholesterol in control, control 
siRNA (SCRM), and LDL-R silenced endothelial cells by Filipin staining. (F) Mitochondrial dysfunction was 
addressed by measuring ΔΨm by flow cytometry. *p<0.01 between control and silenced cells.  
LDL-R, Low Density Lipoprotein Receptor; SCRM, Control siRNA; LDL, Low Density Lipoprotein; HMGCR, 3-Hydroxy-3-
Methylglutaryl-CoA Reductase; SREBP-2, Sterol regulatory element-binding protein 2; NLRP3, nacht Domain-, leucine-
rich repeat-, and PYD-containing protein 3; INSIG, Insulin Induced Gene; SCAP, SREBP cleavage-activating protein; ΔΨm, 





In this work, we have examined the pathophysiology of FH in primary cultured fibroblasts 
derived from 4 patients harboring LDL-R mutations. As a consequence of defective LDL-R, FH 
fibroblasts showed a marked decrease in the incorporation of cholesterol mediated by LDL-R 
(Figure 8 and Figure 22). Interestingly, intracellular cholesterol levels were considerably high in 
FH patients, suggesting that cholesterol biosynthesis was up-regulated. Since the seminal 
works of Brown and Goldstein is well known that defective binding of lipoproteins to cultured 
fibroblasts induces impaired regulation of HMGCR activity (Brown & Goldstein, 1974). This 
binding appears to be a required step in the process by which LDL normally suppresses the 
synthesis of HMGCR, the rate-controlling enzyme in cholesterol biosynthesis. The 
demonstration of a defect in LDL binding appears to explain the failure of lipoproteins to 
suppress the synthesis of this enzyme and hence may account for the overproduction of 
cholesterol that occurs in FH cells. Thus, increased intracellular lipogenesis in FH fibroblasts 
would be a consequence of a constitutive increase of enzymes involved in cholesterol 
synthesis due to defective extracellular cholesterol uptake.  
In addition to elevated cholesterol levels and cholesterogenic enzymes expression, a 
significant decrease in CoQ10 levels associated with down-regulation of proteins involved in 
CoQ10 biosynthesis was also found in FH fibroblasts (Figure 11 and Figure 12). These results 
suggest a possible imbalance in the mevalonate pathway that could affect the synthesis of 
both cholesterol and CoQ10 which eventually provokes cholesterol 
overproduction/accumulation and secondary CoQ10 deficiency. It is also plausible to think that 
a high demand for cholesterol would shift the intermediary substrates flow into one direction 
(steroidogenesis) and decrease a collateral pathway (CoQ10 synthesis).  
In turn, secondary CoQ10 deficiency may impair mitochondrial function  (Cotán et al., 
2011). Thus, our data showed mitochondrial dysfunction associated with high ROS production, 
reduced ATP levels, mitochondrial depolarization and low activity of mitochondrial respiratory 
complexes in FH fibroblasts (Figure 14 and Figure 18). These markers of mitochondrial 
dysfunction have been previously described in several disorders such as fibromyalgia, 
mitochondrial and lysosomal diseases as well as primary or secondary CoQ10 deficiencies  
(Cordero et al., 2010; Cotán et al., 2011; De la Mata et al., 2012). 
In addition, autophagy was examined in FH fibroblasts to determine if mutant cells 
manifested extensive mitophagy as it had been previously described in fibroblasts suffering 
from mitochondrial dysfunction (Cordero et al., 2010; Cotán et al., 2011; De la Mata et al., 
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2012). Our results showed that autophagic genes and autophagic proteins were significantly 
increased in FH fibroblasts. Immunofluorescence examination also revealed colocalization of 
mitochondrial and autophagosome markers indicating mitophagy activation (Figure 13, Figure 
14 and Figure 15). Autophagic flux refers to the whole process of autophagy, including 
autophagosome formation, maturation, fusion with lysosomes, subsequent breakdown and 
the release of degraded molecules into the cytosol, representing the dynamic process of 
autophagy (Xiao-jie Zhang, Chen, Huang, & Le, 2013). Our results indicated that autophagy flux 
was also impaired in FH fibroblasts. This alteration could be responsible for the accumulation 
of engulfed mitochondria by autophagolysosomes in mutant cells.  
Both lipid accumulation and mitochondrial dysfunction have been considered to play 
an important role for inflammation processes (Alcocer-Gómez et al., 2014; Gurung et al., 
2015). Indeed, FH fibroblasts showed cholesterol accumulation, mitochondrial dysfunction and 
inflammasome activation (Figure 16). Inflammatory processes have been  associated with the 
development of an atherosclerotic plaque, which is created by an oxidative modification of LDL 
when it is transported to the arterial wall (Madamanchi & Runge, 2007). According to our 
results, mitochondria dysfunction and CoQ10 deficiency in FH cells can also play an important 
role in the pathophysiology of early atherosclerosis by contributing to increased production of 
free radicals and inflammation in the endothelium of blood vessels. 
                        One of the most consistent hypothesis to explain the premature atherosclerosis  
(Chisolm & Steinberg, 2000) in FH patients postulates that the disease is due to oxidation of 
LDL (Witztum & Steinberg, 1991) by free radicals produced by circulating and vascular wall 
cells (Lamb, Wilkins, & Leake, 1992; Morel, DiCorleto, & Chisolm, n.d.). However, it is not clear 
where and how the conditions are set for the generation of oxidative stress in FH. Increased 
ROS production in isolated mitochondria from liver tissue, cardiac and brain and spleen 
mononuclear cells isolated from LDL-R knockout mice have been reported (Oliveira et al., 
2005).  Thus, the defect in LDL-R leads to two important proatherogenic effects: increased 
levels of oxidized LDL and imbalance of cellular redox state. This latter process would be 
responsible for local stress, which induces lipoprotein oxidation and mitochondrial damage 
(Vindis et al., 2005; Zmijewski et al., 2005). The resulting vicious cycle would cause cell death 
and progress of arteriosclerosis in hypercholesterolemia by the absence of LDL-R. This redox 
imbalance can be important in the pathogenesis of other diseases that also occur with 
increased hyperlipidemia and lipidogenesis such as diabetes, nephrotic syndrome, obesity, and 
metabolic syndrome (Vercesi, Castilho, Kowaltowski, & Oliveira, 2007). Within the vascular 
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wall, increased mitochondrial oxidative stress may contribute to the oxidation of lipoproteins, 
which, along with increased susceptibility to cell death may be a causal effect on the 
development of atherosclerotic lesions. In addition, oxidative stress in mitochondria and 
susceptibility to cell death can contribute to tissue injury of ischemia that occurs in vascular 
accidents (stroke) and heart attacks in FH. 
 
In this project, we proposed that secondary CoQ10 deficiency due to a constitutive 
dysregulation of mevalonate pathway may in part explain the generation of oxidative stress in 
FH cells. Furthermore, mitochondria dysfunction was associated with mitophagy and 
inflammasome activation, and many experimental studies have reported that NLRP3 
inflammasome plays a crucial role in the progression of atherosclerosis (Karasawa & Takahashi, 
2017). Thus, Duewell and colleagues showed that NLRP3‐deficient bone marrow cells 
transplanted into atherosclerosis‐prone low‐density lipoprotein receptor–deficient mice had 
reduced atherosclerosis  (Duewell et al., 2010). 
 
Currently, statins are the main therapeutic option for lowering levels of total 
cholesterol and LDL-C. Statins act by inhibiting HMGCR and their development over the past 20 
years has represented a breakthrough for the treatment of hypercholesterolemia (Jasińska, 
Owczarek, & Orszulak-Michalak, n.d.). Nowadays, the use of statins is well tolerated and they 
have a good safety profile (Bays, 2006). However many adverse effects such as hepatoxicity, 
neuropathies, risk of increased incidence of cancer (Alsheikh-Ali, Maddukuri, Han, & Karas, 
2007), and various forms of myotoxicity mainly from myalgia to rhabdomyolysis have been 
described. These deleterious manifestations of muscle occur in some studies in 1-7% of 
patients treated with statins and do not correlate with the effectiveness on the cholesterol 
lowering drug used (Baer, Miyamoto, & Denver, 2007; Christopher-Stine, 2006). The 
pathophysiological mechanisms of statin-induced myopathy are not fully known. One of the 
proposed mechanisms postulated that myopathy statins is due to a mitochondrial dysfunction 
due to inhibition of the mevalonate pathway which is essential for the synthesis of the 
isoprenoid chain of CoQ10 (P. D. Thompson, Clarkson, & Karas, 2003). In the other hand, CoQ10 
is an essential cofactor in the mitochondrial electron transport (Crane, 2001), and 
mitochondria are essential to the normal functioning of high energy-demanding tissues such as 
muscles. Aftermarket studies have indicated that up 13.6% of patients treated with statins 
experience some degree of myopathy (Scott, Lintott, & Wilson, 1991). The diagnosis of the 
severity of secondary CoQ10 deficiency and mitochondrial impairment in FH patients can be 
89 
 
important to prevent potential myotoxic effects caused by treatment with statins at high 
doses. 
For all above reasons, alternative approaches in FH are based on the evidence that 
statins presumably affect also CoQ10 biosynthesis that is already reduced by an imbalance in 
the CoQ10/cholesterol biosynthetic pathway in FH. In addition, new therapies are necessary for 
patients who cannot reach the target LDL-C level when taking the maximum-tolerated dose of 
a statin or cannot tolerate them. Therefore, treatments focused on reducing intracellular 
cholesterol content and raising CoQ10 levels would be appropriate for neutralizing 
mitochondrial damages and restoring the dysregulated cholesterogenic pathway in FH 
patients.  
SREBPs are membrane-bound basic helix-loop-helix leucine zipper transcription factors 
that serve as master regulators of lipid homeostasis by regulating synthesis of cholesterol, 
fatty acids, and triglycerides (Jeon & Osborne, 2012). The three SREBP isoforms, SREBP-1a, 
SREBP-1c and SREBP-2, have different roles in lipid synthesis (Brown & Goldstein, 1998). In vivo 
studies using transgenic and knockout mice suggest that SREBP-1c is involved in fatty acid 
synthesis and insulin induced glucose metabolism (particularly in lipogenesis), whereas SREBP-
2 is relatively specific to cholesterol synthesis. When sterol levels decrease by reduced uptake, 
as it is the case in FH cells, the precursor is cleaved to activate cholesterogenic genes and 
proteins and maintain cholesterol homeostasis (Horton et al., 2002). Release of membrane-
bound SREBP requires SREBP cleavage-activating protein (SCAP) to escort SREBP from the 
endoplasmic reticulum to the Golgi for cleavage by site-1 and site-2 proteases. Thus, in FH 
fibroblasts the low cholesterol uptake provokes increased SREBP-2 maturation and 
consequently increased cholesterol biosynthesis. However is not clear why increased 
cholesterol biosynthesis persists despite FH cells contain high cholesterol levels. One plausive 
explanation is that FH cells are not able to sense cholesterol accumulation which depends on 
INSIG1 and INSIG2, proteins that interact with and retain SREBPs in the ER, inhibiting their 
activation  (Dong et al., 2012) and negatively regulating HMGCR transcription (Peter J. 
Espenshade & Hughes, 2007; Sever et al., 2003a). Confirming this assumption, cholesterol and 
triglycerides are over-accumulated in INSIGs knockout mice liver (Engelking et al., 2005). Our 
results showed that INSIG1 was practically absent while INSIG2 was significantly reduced in FH 
fibroblasts indicating that cholesterol sensing in ER must be impaired. As a result, SREBP2 was 




Figure 22. Effect of CoQ10 treatment on FH fibroblasts. (A) Effect of CoQ10 on LDL uptake. After 25 μM 
CoQ10 treatment for 72 hours, control and FH fibroblasts were incubated with a fluorescently-labeled LDL 
and examined by fluorescence microscopy. CoQ10 treatment improves the impaired LDL-uptake in FH 
fibroblasts. (B) Quantification LDL-uptake by Image-J software. (C) Western blot analysis of LDL-R and Coq1 
expression levels under increasing concentrations of CoQ10 (1-50 μM) in patient fibroblasts (P1). Data 
represent the mean±SD of three separate experiments. Actin was used as a loading control. *p<0.01 
between control and FH fibroblasts. ap <0.05 between the presence and the absence of CoQ10 treatment. 
CoQ10, Coenzyme Q10; LDL, Low Density Lipoprotein; FH, Familial Hypercholesterolemia; SD, Standard 
Deviation; A.U., arbitrary units. 
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Studies have shown that the regulatory actions of INSIGs in cholesterol metabolism are 
critically dependent on the ratios of INSIG proteins to their targets SCAP and HMCGR (Sever et 
al., 2003a; Yang et al., 2002). Thus, over-expression of SCAP or HMCGR saturates endogenous 
INSIGs, and impairs the proper regulation of cholesterol synthesis (P. C. W. Lee, Liu, Li, & 
Debose-Boyd, 2007). Therefore, a high ratio of SCAP to INSIGs, as we found in FH fibroblasts, 
may diminish sterol sensitivity of SREBP processing. Conversely, when INSIGs levels rise under 
CoQ10 treatment, SREBP processing can be inhibited by lower concentrations of sterols (Yang 
et al., 2002).  These findings highlight the importance of SCAP-INSIGs ratios in normal sterol-
regulated processing of SREBPs in FH cells. 
 Our results also showed that both increased cholesterol levels and mitochondrial 
dysfunction can be restored by treatment with CoQ10, a well-known player in cellular 
bioenergetics (Figure 17, Figure 18, Figure 19, Figure 22 and Figure 23). CoQ10 has been 
reported to induce AMPK activation (Garrido-Maraver et al., 2015) and PPAR-α expression via 
the calcium-mediated AMPK signal pathway (S. K. Lee et al., 2012). CoQ10 increases the 
expression of PPAR-α at both the mRNA and protein levels. Furthermore, knock down of AMPK 
with siRNA or inhibition of AMPK using the AMPK inhibitor compound C blocked CoQ10-
induced expression of PPAR-α, indicating that AMPK plays a critical role in PPAR-α induction. 
On the other hand, AMPK has been reported to inhibit the cleavage and transcriptional 
activation of SREBP-2, via direct phosphorylation (Li et al., 2011). Additionally, PPAR-α can 
inhibit cholesterol biosynthesis via reduction in SREBP-2 maturation (König et al., 2007). This, 
in turn, may reduce the expression levels of HMGCR, squalene synthase and other 
cholesterogenic proteins. Our results suggest that CoQ10 could reduce cholesterol biosynthesis 
through AMPK-mediated PPAR-α stimulation. Interestingly, CoQ10 treatment increases the 
expression levels of COQ1, COQ2 and COQ7, which have been reported to be under PPAR-α 
regulation (Bentinger et al., 2008). In addition, CoQ10 treatment increased INSIG1 and INSIG2 
expression levels which are also regulated by PPAR-α (König et al., 2007; J.-H. Lee et al., 2017). 
This restoration of INSIGs expression may allow a correct detection of cholesterol levels in ER 
membranes and proper feedback inhibition of the cholesterogenic pathway. All the beneficial 
effects of CoQ10 on mevalonate pathway were accompanied by improvement of cell 






Figure 23. Effect of AMPK inhibition by compound C on CoQ10 treatment. (A) Control and FH 
fibroblasts were treated with 25 μM CoQ10 in the presence of 10 μM compound C (CC), an AMPK 
inhibitor, for 72 hours. Western blot analysis of AMPK, PPAR-α, Coq2, Coq7, lanosterol synthase, 
PCSK9 and NLRP3. Actin was used as a loading control. (B) Densitometry of Western blotting. *p<0.05 
between control and FH fibroblasts. #p<0.01 between the presence and the absence of CoQ10 
treatment.  
AMPK, AMP-activated protein kinase; CC, compound C; CoQ10, Coenzyme Q10; PPAR-α, peroxisome proliferator-
activated receptors alpha; PCSK9, Proprotein convertase subtilisin/kexin type 9 ; NLRP3, nacht Domain-, leucine-
rich repeat-, and PYD-containing protein 3; A.U., arbitrary units 
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Several studies have reported that AMPK activation reduced lipid synthesis by 
restraining SREBP activity and led to fatty acid oxidation in the liver to control hepatic energy 
metabolism (Viollet et al., 2006). On the other hand, CoQ10-mediated activation of AMPK 
and/or PPAR-α may induce LDL-R upregulation as previously reported (Brusq et al., 2006; 
Huang et al., 2009). Although, it is known that LDL-R gene promoter activity is enhanced 
through the proteolytic activation of SREBP-2 and SREBP-1 (Yashiro, Nanmoku, Shimizu, Inoue, 
& Sato, 2012), our results showed that LDL-R expression and LDL uptake were markedly 
increased after CoQ10 treatment despite reduced maturation of SREBP-2 (Figure 22). These 
findings suggest that LDL-R expression may be regulated by other molecular mechanisms 
possibly mediated by AMPK and/or PPAR-α. In agreement with these results, Schmelze et al. 
found that treatment with the reduced form of CoQ10 in humans induced characteristic gene 
expression patterns, which were translated into reduced LDL-C levels (Schmelzer et al., 2011). 
Other report also suggested that CoQ10 improved the hypolipemiant action of statins (Kang, 
Yang, Kang, Ryou, & Kang, 2012). CoQ10 has been intensively implicated in protecting against 
chronic diseases, especially atherosclerosis (Garrido-Maraver et al., 2014). As increased ROS 
levels can modify cell-signaling proteins (including transcription factors and ion channel 
proteins) and have pathological consequences particularly in endothelial cells, it has been 
proposed that the antioxidant properties of CoQ10 may also contribute to its beneficial effects 
on atherosclerosis (B.-J. Lee, Huang, Chen, & Lin, 2012a, 2012b).  
In addition, CoQ10 has been proposed to exert its atheroprotective effects partially by 
promoting miRNAs-mediated cholesterol efflux by inducing ABCA1 and ABCG1 expression  (D. 
Wang et al., 2014; Yan et al., 2015) which have been shown to be critically involved in 
cholesterol and phospholipid efflux in macrophages, hepatocytes, and intestinal mucosa cells 
(Kerr, Haider, & Gelissen, 2011; Velamakanni, Wei, Janvilisri, & van Veen, 2007). Supporting 
these results, we found that CoQ10 treatment of FH fibroblasts markedly induced ABCA1 
expression. 
The therapeutic effect of CoQ10 in cardiovascular diseases has been reported to be 
caused by improving cardiovascular function, preventing LDL oxidation (Belardinelli, Tiano, & 
Littarru, 2008), and inhibiting atherosclerotic processes (Singh et al., 2003).  There are also 
evidences showing that CoQ10 has a positive effect on atherosclerotic processes improving 
endothelial function indices (Adarsh, Kaur, & Mohan, 2008; Tiano et al., 2007). In a study 
performed by Huynh and co-workers in diabetic patients, CoQ10 decreased oxidative stress, 
improved lipid profiles, and remodeled left ventricle function (Huynh et al., 2012). Moreover, it 
94 
 
has been shown that oral prescription of CoQ10 can decrease atherosclerotic damages in ApoE-
deficient mice (Witting et al., 1999). 
Our results illustrate that dysregulated mevalonate pathway associated with high 
intracellular cholesterol content and mitochondrial dysfunction as well as extensive mitophagy 
and inflammasome activation may participate in FH pathophysiology (Figure 24). 
 
Figure 24. Working model of FH physiopathology. Low expression of LDL-R results in dysregulated 
mevalonate pathway which leads to cholesterol accumulation and secondary CoQ10 deficiency. As a 
consequence, mitochondrial dysfunction produces oxidative stress and mitophagy and inflammasome 
activation. 
FH, Familial Hypercholesterolemia; LDL-R, Low Density Lipoprotein Receptor; CoQ10, Coenzyme Q10 
 
AMPK activation by CoQ10 treatment reduced SREBP-2 activation and cholesterol 
content in FH fibroblasts (Figure 25). This finding could be of great interest because AMPK 
activation has been proposed as a valuable approach to target lipid disorders (Ruderman & 




Figure 25. Working model of the impact of CoQ10 treatment in FH. CoQ10 treatment can correct both 
altered mevalonate pathway and mitochondrial function in FH fibroblasts. CoQ10 causes a significant 
increase expression of LDL-R and ABCA1 accompanied by downregulation of PCSK9. In addition, CoQ10 
restores INSIG1 and INSIG2 expression levels and allows the feedback inhibition of SREBP-2 activation 
when cholesterol levels are high. The beneficial effects of CoQ10 on mitochondrial function can also be 
attributed to CoQ10 biosynthetic pathway up-regulation. 
CoQ10, Coenzyme Q10; FH, Familial Hypercholesterolemia; LDL-R, Low Density Lipoprotein Receptor; ABCA1, ATP-
binding cassette transporter; PCSK9, Proprotein convertase subtilisin/kexin type 9; INSIG, Insulin Induced Gene; 
SREBP-2, Sterol regulatory element-binding proteins 
 
Furthermore, CoQ10 treatment improved mitochondrial function, up-regulated LDL-R 
expression levels and restored INSIGs expression in FH fibroblasts. Its underlying mechanism is 
proposed to be mediated by the activation of AMPK and the concomitant up-regulated 
expression of PPAR-α. Therefore, CoQ10 can be considered as a promising adjuvant 
pharmacotherapy of FH with the putative benefit of improving mitochondrial function and 
preventing inflammation. However, these results need to be confirmed using a larger sample 





1. Fibroblasts derived from patients with familial hypercholesterolemia caused by 
mutations in LDL-R show low expression LDL-R expression levels, defective LDL-C 
uptake and increased intracellular cholesterol biosynthesis. 
 
2. Intracellular cholesterol accumulation in mutant fibroblasts is associated with 
constitutive SREBP-2 activation and low expression levels of INSIG1 and INSIG2, two 
essential proteins involved in cholesterol sensing. 
 
3. LDL-R mutant fibroblasts show a dysregulated mevalonate pathway accompanied by 
increased cholesterogenic genes expression and decreased CoQ10 biosynthesis genes 
expression. 
 
4. Defective CoQ10 biosynthesis in mutant fibroblasts induce mitochondrial dysfunction 
associated with increased oxidative stress, and reduced ATP production and 
mitochondrial mass. 
 
5. Altered mitochondrial function in LDL-R mutant fibroblasts was associated with 
mitophagy and inflammasome activation accompanied by increased IL-1β and IL-18 
production. 
 
6. LDL-R gene silencing in endothelial cells (EA.hy926) reproduce the cellular alteration of 
patient-derived fibroblasts. Silenced endothelial cells show reduced LDL-C uptake, 
altered cholesterogenic and CoQ10 gene expression and intracellular cholesterol 
accumulation. 
 
7. Supplementation of mutant fibroblasts with CoQ10 correct most of the 
pathophysiological alterations in mutant fibroblasts such as LDL-R expression levels, 
dysregulated mevalonate pathway, intracellular cholesterol accumulation, 
mitochondrial dysfunction and increased mitophagy and inflammasome activity. 
 
8. Fibroblast cell cultures derived from patients with familial hypercholesterolemia are 
useful cellular models for understanding pathophysiological alterations and the 
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